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Abstract 
 
Introduction: Anthracyclines, such as doxorubicin (DXR), are among the most valuable treatments 
for various cancers, but their clinical use is limited due to detrimental side-effects such as 
cardiotoxicity. The abundance of mitochondria in cardiomyocytes closely links mitochondrial function 
with myocardial function. Mitochondrial dysfunction has emerged as a critical element in the 
development of DXR-induced cardiotoxicity. In light of this scenario, melatonin (MLT) is a potent 
anti-oxidant, is non-toxic, is dually oncostatic and cardio-protective, and has been shown to influence 
mitochondrial homeostasis and function. Both endogenously produced and exogenously 
administered MLT during or prior chemotherapy shows great promise in this therapeutic avenue as 
demonstrated in several studies. Although research support the mitochondrial protective role of MLT, 
the exact mechanisms by which MLT confers mitochondrial protection in the context of DXR-induced 
cardiotoxicity remains to be elucidated.  
Aims: The aim of this study was to investigate the effect of MLT on the following mitochondrial and 
cellular parameters: mitochondrial reactive oxygen species (ROS) production, mitochondrial 
membrane potential, mitochondrial fission and fusion, mitochondrial bioenergetics and biogenesis, 
sirtuin activity, autophagy and cell death in an in vitro model of DXR-induced cardiotoxicity. 
Furthermore, the effect of MLT on cardiac function and tumor growth was assessed in a tumor-
bearing rat model of acute DXR-induced cardiotoxicity.  
Materials and Methods: H9c2 rat cardiomyoblasts were pre-treated with MLT (10 µM) for 24 hours 
followed by DXR treatment (3 µM) for 24 hours. Following treatment, the above mentioned 
mitochondrial and cellular parameters were assessed using immunoblot analysis, mitochondrial 
respiration analysis, flow cytometry, fluorescence microscopy and luciferase-based assays. 
Sprague Dawley female rats (16-18 weeks old), were inoculated with LA7 rat tumor cells. Animals 
received DXR (3 intraperitoneal injections of 4 mg/kg at 3-day intervals, 12 mg/kg cumulative dose) 
and/or received MLT (6 mg/kg) daily in their drinking water. Tumors were measured daily using 
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digital calipers and tumor volumes calculated. Animal weights were recorded daily. Rat hearts were 
used to conduct isolated heart perfusions to assess cardiac function and thereafter, heart tissue was 
used for immunoblot analysis. 
 
Results: DXR treatment significantly increased cell death, mitochondrial ROS levels and 
mitochondrial fission and these effects were significantly reduced with MLT pre-treatment. 
Furthermore, MLT pre-treatment significantly increased mitochondrial membrane potential, 
mitochondrial biogenesis and cellular ATP levels reduced by DXR treatment. 
Cardiac output and total work performance of the heart was significantly increased in rats treated 
with DXR+MLT in comparison to rats treated with DXR alone. In addition, body and heart weights 
were significantly reduced in DXR-treated rats in comparison to DXR+MLT treated rats. Tumor 
volumes were significantly reduced in DXR+MLT-treated rats on Day 8 in comparison to DXR-treated 
rats. 
Discussion and Conclusion: The results obtained from the current study indicates that MLT 
treatment confers a cardio-protective effect by maintaining mitochondrial function, increasing 
cardiomyocyte survival and improving cardiac function during DXR-induced cardiotoxicity. 
Furthermore, MLT treatment alone suppresses the growth of tumors. The combination of DXR+MLT 
treatment rapidly reduced tumor growth, suggesting that MLT enhances the oncostatic activity of 
DXR. The unique ability of MLT to be both cardio-protective and oncostatic during DXR-induced 
cardiotoxicity is promising for the field of cardio-oncolocgy. 
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Opsomming 
 
Inleiding: Antrasikliene, soos doxorubicin (DXR), is van die mees waardevolle behandelings-opsies 
vir verskeie tipes kankers, maar die kliniese gebruik daarvan word deur die nadelige newe-effekte 
beperk, wat kardiotoksisiteit insluit. Die groot hoeveelheid mitochondria in kardiomiosiete verbind 
mitochondriale funksie aan kardiale funksie. Na aanleiding hiervan, is daar al bewys dat melatonien 
(MLT), ‘n kragtige antioksidant, nie-toksies, gelyktydig onkostaties en kardio-beskermend, 
mitochondriale homeostase en funksie kan beïnvloed. Dit is al in verskeie navorsing bewys dat beide 
endogeen geproduseerde en eksogeen toegediende MLT tydens en voor chemoterapie groot belofte 
as behandelings-opsie inhou. Alhoewel navorsing al die beskermende rol van MLT bewys het, moet 
die presiese meganisme waardeur MLT mitochondria beskerm in die konteks van DXR-
geïnduseerde kardiotoksisiteit, nog bepaal word.  
Doelwitte: Die doel van hierdie studie was om die effek van MLT op die volgende mitochondriale 
en sellulêre parameters in ‘n in vitro model van DXR-geïnduseerde kardiotoksisiteit te bepaal: 
Mitochondriale reaktiewe suurstofspesie produksie, mitochondriale membraanpotensiaal, 
mitochondriale splyting en fusie, mitochondriale bio-energie produksie en biogenese, sirtuin 
aktiwiteit, autofagie asook seldood. Die effek van MLT op kardiale funksie en tumorgroei is ook in ‘n 
tumor-draende rot model van akute DXR-geïnduseerde kardiotoksisiteit geondersoek. 
Materiaal en Metodes: H9c2 rot kardiomioblaste is met MLT (10 M) vir 24 uur behandel voordat 
die met DXR (3 M) ook vir 24 uur behandel is. Na behandeling is die bo-vermelde mitochondriale 
en sellulêre parameters bepaal deur middel van immunoblot bepalings, mitochondriale analises, 
vloeisitometrie, fluoressensie mikroskopie en lusiferase-gebaseerde bepalings. 
Sprague Dawley vroulike rotte (16-18 weke oud) is met LA7 rot tumorselle geïnokuleer. Die rotte het 
DXR (3 intraperitoneale inspuitings van 4 mg/kg met 3-dag intervalle en ‘n 12 mg/kg kumulatiewe 
dosis) en/of MLT (6 mg/kg) daagliks in hul drinkwater ontvang. Tumore is daagliks met ‘n digitale 
meetpasser gemeet en tumor volumes is bereken. Die rotte is ook daagliks geweeg. Rotharte is 
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geïsoleer en geperfuseer om kardiale funksie te bepaal en daarna is dit vir immunoblot analises 
gebruik. 
Resultate: DXR behandeling het seldood geïnduseer, mitochondriale reaktiewe suurstofspesie 
vlakke verhoog en het ook mitochondriale splyting veroorsaak. Hierdie negatiewe effekte van DXR 
is beduidend verminder wanneer die selle vooraf met MLT behandel is. MLT behandeling het ook 
mitochondriale membraanpotensiaal, mitochondriale biogenese en sellulêre ATP vlakke verhoog 
wat deur DXR behandeling verlaag was. 
Kardiale omset en kardiale werkverrigting van die harte was beduidend verhoog in rotte wat met 
beide DXR en MLT behandel is in vergelyking met harte van die DXR behandelde rotte. Verder is 
die liggaamsgewig en die massas van die harte ook beduidend verlaag in vergelyking met die DXR 
en MLT behandelde rotte. Tumor volumes is ook alreeds beduidend verlaag op dag 8 in die DXR en 
MLT behandelde rotte in vergelyking met die DXR behandelde rotte. 
Bespreking en Gevolgtrekking: Die resultate van hierdie studie bewys onteenseglik dat MLT 
behandeling sy kardio-beskermende effekte tydens DXR-geïnduseerde kardiotoksisiteit 
teweegbring deur mitochondriale funksie te handhaaf, asook om kardiomiosiet oorlewing en kardiale 
funksie te verbeter. Verder kan MLT behandeling op sy eie ook tumor-groei onderdruk. Die 
kombinasie van DXR en MLT behandeling het tumor-groei vinniger geonderdruk wat moontlik ‘n 
bewys is dat MLT die onkostatiese aktiwiteit van DXR kan verhoog. Hierdie unieke vermoë van MLT 
om beide kardio-beskermend en onkostaties tydens DXR- geïnduseerde kardiotoksisiteit te wees, 
maak van MLT ‘n belowende terapeutiese opsie in die veld van kardio-onkologie. 
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Chapter 1 
 
Literature Review 
 
1.1 Introduction 
Since its discovery in the late 1960s, the anthracycline antibiotic doxorubicin (DXR) has been one of 
the most effective and generally prescribed chemotherapeutic drugs for the treatment of various 
cancers (Weiss, 1992; Octavia et al., 2012; Bonadonna et al., 1970). The eminent use of this potent 
antineoplastic agent is subdued by several severe side effects one of which, cardiotoxicity, is of 
particular concern. Patients suffering from DXR-induced cardiotoxicity may clinically present with 
acute, subacute, or early/late-onset chronic progressive forms, all of which result in heart failure. 
Such a complication poses a major clinical obstacle as the prognosis for heart failure in this cohort 
of patients remains poor: 50% die within 2 years, emphasising the urgent need for novel or adjuvant 
therapeutic agents (Steinherz et al., 1991; Von Hoff et al., 1979; Ganz et al., 2008). 
Over the decades, numerous studies sought to identify the intracellular targets and elucidating the 
molecular mechanisms involved in DXR-induced cardiotoxicity (Minotti et al., 2004; Olson and 
Mushlin, 1990; Singal et al., 1997). These studies have contributed to the theory that it is in fact a 
multifactorial process that leads to cardiomyocyte death as the terminal downstream event (Minotti 
et al., 2004; Kalyanaraman et al., 2002; Fukazawa et al., 2003). Mitochondrial dysfunction has 
become an apparent hallmark of DXR-induced cardiotoxicity (Tokarska-Schlattner et al., 2006). 
Abnormalities in mitochondrial functions such as defects in the respiratory chain/oxidative 
phosphorylation (OXPHOS) system, decreased adenosine tri-phosphate (ATP) production, a switch 
in metabolic substrate utilization, mitochondrial deoxyribonucleic acid (DNA) damage, modulation of 
mitochondrial sirtuin activity, and a vicious cycle of free radical formation have all been suggested 
as the primary causative factors in the pathogenesis of DXR-induced cardiotoxicity (Olson and 
Mushlin, 1990; Tokarska-Schlattner et al., 2006; Verma et al., 2013). These defects act 
synergistically to create a bioenergetic crisis, which culminates in cardiomyocyte death. 
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In view of the above-mentioned, the general clinical approach to attenuate DXR-induced 
cardiotoxicity is to utilize antioxidants. Melatonin (MLT), also known as the ‘dark hormone,’ has shed 
light on this therapeutic avenue as demonstrated in various studies (Kim et al., 2005; Sahna et al., 
2003; Ahmed et al., 2005; Eser et al., 2006). The promising effects of this pineal indoleamine are 
attributed to it being a free radical scavenger of high potency, having low toxicity, exhibiting good 
solubility in both aqueous and organic phases, influencing mitochondrial homeostasis and 
functioning, and being dually oncostatic and cardioprotective (Reiter et al., 2008; Leon et al., 2008; 
García et al., 2014; Tengattini et al., 2008). Furthermore, a number of in vivo studies have shown 
that MLT is significantly superior to the classic antioxidants, such as vitamin E, β-carotene, and 
vitamin C, as well as garlic oil, in enhancing free radical destruction (Gultekin et al., 2001; Rosales-
Corral et al., 2003; Anwar and Meki, 2003). However, the exact mechanisms by which MLT confers 
protection and the key cellular parameters that it influences remain to be elucidated. 
The role of MLT regarding the detrimental effects of DXR on mitochondrial function, such as 
bioenergetics failure, free radical generation, and cardiomyocyte cell death will be discussed in this 
literature review. Furthermore, some of the key parameters associated with mitochondrial 
dysfunction which lack evidence to support the role of MLT in the context of cardiotoxicity are briefly 
highlighted. 
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1.2 Mitochondria: a common target for melatonin and doxorubicin 
Mitochondria, which are organelles present in all cells of the human body except erythrocytes, play 
a pivotal role in energy production. In addition to this vital function, mitochondria are involved in other 
complex processes such as heme metabolism, maintaining homeostatic control of reactive oxygen 
and nitrogen species production, calcium regulation, cellular metabolism and proliferation, cell 
division and programmed cell death (apoptosis), and in house-keeping functions of mitophagy and 
mitochondrial dynamics (Gustafsson and Gottlieb, 2008; Cardinali et al., 2013; Szewczyk and 
Wojtczak, 2002; Schaper et al., 1985; Ventura-Clapier et al., 2004). Mitochondria are abundant in 
heart tissue, constituting about 45% of the myocardial volume (Marin-Garcia et al., 2001; Gottlieb 
and Gustafsson, 2011) in comparison with other tissues. This abundance is due to the high energy 
demand of the heart that is satisfied during mitochondrial respiration which generates ATP, of which 
more than 90% is utilized by cardiomyocytes (Tokarska-Schlattner et al., 2006). 
The abundance of mitochondria in cardiomyocytes closely links mitochondrial bioenergetics with 
myocardial function and viability; thus, mitochondrial dysfunction has recently been recognized as a 
pivotal element in the development of DXR-induced cardiotoxicity. Supporting this notion, it has been 
demonstrated that DXR specifically targets mitochondria and accumulates in these organelles at 
concentrations 100-fold higher than in plasma (Tokarska-Schlattner et al., 2007; Sokolove, 1994). 
This accumulation is greatly attributed to the cationic nature of DXR that has a high affinity to 
cardiolipin, a negatively charged and major phospholipid component in the inner mitochondrial 
membrane. The binding of DXR to cardiolipin leads to the formation of an irreversible complex 
(Goormaghtigh et al., 1980; Goormaghtigh et al., 1986), inhibiting oxidative phosphorylation as it 
renders cardiolipin incapable of acting as a cofactor for mitochondrial respiratory enzymes. MLT has 
been reported to protect the mitochondria by preventing cardiolipin oxidation which would otherwise 
promote the mitochondrial transition pore opening (mPTP), resulting in cell death (Paradies et al., 
2010). 
In light of this scenario, mitochondria are also a common target for MLT. In fact, in a recent review 
by Tan and colleagues (2013), it has been hypothesized that mitochondria were the initial sites of 
Stellenbosch University  https://scholar.sun.ac.za
4 | P a g e  
 
MLT biosynthesis during the early stages of endosymbiosis. The review summarizes crucial 
evidence in support of the proposed theory that mitochondria may have the ability to independently 
synthesize MLT (for review see Tan et al., 2013). Attributed to this molecule’s amphiphilic properties, 
MLT readily crosses all biological barriers and gains access to all compartments of the cell, thus 
highly concentrating in the mitochondria and the nucleus (Acuna-Castroviejo et al., 2014; Venegas 
et al., 2012; Escames et al., 2010; Menendez-Pelaez et al., 1993; Pablos et al., 1996). It is important 
to note that MLT concentrations in the cell membrane, cytosol, nucleus, and mitochondria fluctuate 
independently of the circadian rhythm during a 24-hr period (Venegas et al., 2012). It may be possible 
that MLT changes its levels to satisfy the antioxidant demand of each subcellular compartment. From 
a therapeutic perspective, clinicians should bear in mind that the subcellular levels of MLT are 
controlled by regulatory mechanisms, and therefore, MLT has low toxicity when administered at high 
doses (Venegas et al., 2012). Furthermore, the use of MLT at high doses has been shown to be 
essential in reaching adequate subcellular concentrations to exert its pharmacological effects 
(Venegas et al., 2012). 
An emerging regulatory pathway that plays a role in controlling mitochondrial function is the 
posttranslational modification (PTM) of mitochondrial proteins via acetylation/deacetylation of protein 
lysine residues (Sack, 2011). PTM is modified by nutrient flux and redox stress, thus influencing 
mitochondrial proteins controlling fat oxidation, the tricarboxylic acid (TCA) cycle, the electron 
transport chain (ETC), and controlling redox stress (Zhao et al., 2010). Three mitochondrial 
deacetylation enzymes have been identified, namely sirtuin-3, sirtuin-4, and sirtuin-5 (SIRT3-5) 
(Schwer and Verdin, 2008) with SIRT3 being found to be the most robust mitochondrial deacetylase 
(Sack, 2011; Lombard et al., 2007). In addition to its established mitochondrial function, SIRT3 is 
also a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria in 
response to various stressors, including ultraviolet (UV) irradiation and the chemotherapeutic drug, 
etoposide (Scher et al., 2007). 
Interestingly, a major mechanism by which DXR elicits its antitumor activity is via double-stranded 
DNA breaks (DSB), and SIRT3 has been shown to protect cardiomyocytes from stress-induced cell 
death at least in part by deacetylating and activating the DSB repair protein (Sundaresan et al., 
Stellenbosch University  https://scholar.sun.ac.za
5 | P a g e  
 
2010). Another study demonstrated that in contrast to SIRT3, downregulation of SIRT4 expression 
renders mitochondria resistant to mPTP induction. Thus, the suppression of mitochondrial SIRT4 
protected against mPTP-dependent cytotoxicity induced by DXR (Verma et al., 2013). On the other 
hand, MLT was first implicated in modulating nuclear SIRT1 during the biological process of aging 
as well as in cancer (Jung-Hynes et al., 2010; Jung-Hynes et al., 2010). Such evidence potentially 
implies that MLT may have the ability to favourably modulate mitochondrial sirtuins during DXR-
induced cardiotoxicity. However, this remains to be elucidated. In the ensuing sections of this 
literature review, the focus is on the adverse effects of DXR on key mitochondrial parameters and 
the mechanism by which MLT can potentially mitigate mitochondrial dysfunction during DXR-induced 
cardiotoxicity. 
 
1.3 The role of melatonin in doxorubicin-induced bioenergetic failure 
The heart is a vital organ demanding vast amounts of energy to sustain its contractile functioning. 
Mitochondrial respiration is responsible for generating 90% of this energy in the form of ATP via the 
respiratory chain (Ventura-Clapier et al., 2004). The respiratory chain, which is located in the inner 
mitochondrial membrane, contains a series of electron carriers grouped into four enzyme complexes: 
complex I (NADH dehydrogenase); complex II (succinate dehydrogenase); complex III (cytochrome 
c reductase); and complex IV (cytochrome c oxidase). The synthesis of ATP via the respiratory chain 
involves two coupled processes: electron transport and oxidative phosphorylation (OXPHOS) 
(Mitchell et al., 1967).  
Disruption of cardiac energy homeostasis is a critical feature of DXR-induced cardiotoxicity. The 
intracellular ATP pools in the heart are very small (5 mmol/kg heart wet weight). When energy 
demand is increased, these ATP pools may be replenished from larger intracellular pools of 
phosphocreatine (PCr) (10 mmol/kg heart wet weight) (Meininger et al., 1999). Creatine kinase (CK) 
is responsible for the conversion of creatine to phosphocreatine and acts as a modulator of the 
energy reservoir (Thomas et al., 1994; Beer et al., 2002). DXR is known to accumulate ferrous iron 
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which in turn induces oxidative damage to CK, disrupting energy homeostasis by decreasing both 
ATP and PCr levels (Ichikawa et al., 2014). 
In an in vivo study, Eidenschink and colleagues (2000) reported a 20% decrease in PCr/ATP ratio 
in children 4 years post-DXR treatment even in the absence of clinical manifestations of 
cardiomyopathy. When assessing ATP levels, it is important to bear in mind that ATP levels may 
also diminish due to activation of apoptosis and calcium-dependent proteases. Tokarska-Schlattner 
et al. (2005) demonstrated in an isolated perfused rat heart that acute DXR-induced cardiac 
dysfunction may impair energy signaling via the energy sensor AMP-activated protein kinase 
(AMPK), which is associated with mitochondrial dysfunction. 
In addition, as mentioned previously, DXR has a high affinity for cardiolipin (Goormaghtigh et al., 
1980), an integral component of the inner mitochondrial membrane. The binding of DXR to cardiolipin 
does not allow for cardiolipin interaction with key respiratory complexes (Goormaghtigh et al., 1980). 
As the inner mitochondrial membrane represents a critical site for DXR accumulation, the respiratory 
chain can be considered a potential target for DXR-induced toxicity. Numerous studies have 
demonstrated that DXR disrupts mitochondrial respiration at multiple levels, by inhibiting complexes 
of the respiratory chain or inhibiting phosphorylation steps and inducing partial uncoupling (Gosalvez 
et al., 1974; Vidal et al., 1996; Sayed-Ahmed et al., 2000; Jeyaseelan et al., 1997). 
In particular, studies aimed at determining the sensitivity of respiratory complexes to DXR found that 
DXR-sensitive sites were mainly located in complex I, III, and IV, with a specific vulnerability for 
complexes I (NADH dehydrogenase) and IV (cytochrome c oxidase) (Goormaghtigh et al., 1986; 
Marcillat et al., 1989; Nicolay et al., 1987). Other findings further indicate inactivation of complex II 
(Muraoka and Miura, 2003; Bianchi et al., 1987); however, the variation in these results may have 
been influenced by the type of model used. For instance, drug distribution, binding specificity, and 
drug metabolism, via iron, peroxidase systems, or other metabolic pathways, are crucial parameters 
excluded in models of isolated mitochondria. The effect of DXR on mitochondrial respiration results 
in a bioenergetic decline, and this is considered a hallmark of impaired cardiac function in the onset 
and progression of DXR-induced cardiotoxicity. 
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The ability of MLT to influence mitochondrial energy homeostasis has been tested in various in vivo 
and in vitro models (Martin et al., 2000; Tan et al., 2000; Martin et al., 2002; Liu et al., 2013). MLT 
was found to increase the activity of the brain and liver mitochondrial respiratory complexes I and IV 
30 min after its administration to rats, and the activity of these complexes returned to basal levels at 
120–180 min post-treatment. However, the activity of complexes II and III remained unaffected 
(Martin et al., 2000). These findings suggest that MLT has the potential to directly affect mitochondria 
within the hormone’s half-life range. It was also found that MLT administration was able to counteract 
the reduced activity of complexes I and IV in the presence of ruthenium red, an inorganic polycationic 
complex, which causes mitochondrial uncoupling (Martin et al., 2000). MLT was further found to 
prevent cyanide-induced inhibition of complex IV and increased ATP synthesis in both untreated and 
cyanide-treated mitochondria, suggesting that MLT not only directly affects mitochondrial energy 
metabolism but also provides a homeostatic mechanism for the regulation of mitochondrial function 
(Yamamoto and Mohanan, 2002). 
A recent study demonstrated the impact of MLT treatment on the proliferation and differentiation of 
rat dental papilla cells and dentine formation by modulating the activity of mitochondrial complexes 
I and IV (Liu et al., 2013). This finding not only supports the direct action of MLT on mitochondrial 
complexes I and IV, but also the versatile nature of MLT that enables it to influence various biological 
processes. In context of the heart, MLT increased complex IV activity, improved cardiac function with 
a higher left ventricular ejection fraction, and decreased the mortality rate in a model of septic heart 
injury (Zhang et al., 2013). The exact mechanism by which MLT increases the activity of these 
respiratory complexes is, however, unknown, and thus, the effect of MLT at the level of gene 
transcription should also be considered. 
Studies regarding the direct effect of MLT on the mitochondrial respiratory chain and complexes 
during DXR-induced cardiotoxicity seem to be lacking. As a result of the specific interaction of MLT 
with complexes I and IV, future studies should consider assessing the effect of MLT on the reduced 
activity of complexes I and IV induced by DXR, as these specific complexes are vulnerable to the 
toxic effects of DXR. However, the assessment of mitochondrial complex III would be equally 
valuable in this scenario as it plays a critical role in electron transfer and OXPHOS. The method 
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used currently to assess mitochondrial complex III activity involves spectrophotometrically 
measuring the activity of cytochrome c reductase in isolated mitochondria (Fu et al., 2013). A major 
limitation of this method is that during the isolation process of mitochondria, the cytoplasmic 
microenvironment niche that contains critical regulatory mechanisms of mitochondrial function is 
depleted, and therefore, this method may not accurately indicate cellular mitochondrial complex III 
function. To overcome this experimental limitation, the use of intact cells would be highly 
advantageous. 
Fu and colleagues (2013) have developed a novel and effective method to measure mitochondrial 
complex III function in intact cells. This method exploits the fluorogenic property of MLT-induced 
oxidation of 2, 7-dichloro-dihydrofluorescein and the use of this effective and reliable method should 
be considered in future research. It is important to note that the beneficial effects of MLT on 
mitochondrial respiration are independent of its antioxidant activity but are the result of its high redox 
potential (0.94 V) (Tan et al., 2000). This unique property allows for MLT to interact with the 
complexes of the ETC and donate and accept electrons thereby increasing the electron flow, an 
effect not exhibited by other antioxidants (Martin et al., 2000). 
During DXR-induced cardiotoxicity, cardiac remodeling occurs, which initiates a switch in metabolic 
substrate utilization from fatty acids to glucose (Tokarska-Schlattner et al., 2006; Tokarska-
Schlattner et al., 2005). This is as an adaptive response to decreased ATP output (Tokarska-
Schlattner et al., 2006; Tokarska-Schlattner et al., 2005). Fatty acids in the heart are known to be 
the primary substrate utilized for ATP generation under aerobic conditions. During the early stages 
of developing cardiac pathologies, there is a decrease in fatty acid oxidation, which is compensated 
for by an upregulation of glucose utilization. Disrupted fatty acid metabolism has been found in cell 
culture and animal models as well as in humans following treatment with DXR (Thomas et al., 1994; 
Tokarska-Schlattner et al., 2005; Wakasugi et al., 1993; Abdel-Aleem et al., 1997; Saito et al., 2000; 
Kitagawa et al., 2002). Rats treated with DXR showed a significant decrease in fatty acid substrate 
utilization in comparison with glucose (Vidal et al., 1996). On the other hand, Wakasugi and 
colleagues (Wakasugi et al., 1993) indicated that DXR-induced cardiomyopathy is associated with a 
decrease in both fatty acid and glucose utilization. 
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In addition, decreased oxidation of palmitate, a long-chain fatty acid substrate, was demonstrated in 
isolated cardiomyocytes acutely treated with DXR (Bordoni et al., 1999), which could possibly have 
been attributed to the impairment of carnitine palmitoyl transferase 1 (CPT1) and/or depletion of its 
substrate L-carnitine by DXR. Importantly, reduced oxidation and excessive accumulation of fatty 
acids not only induces disruptions at the energy substrate level, but also alters the energy-coupling 
properties of mitochondria (Iliskovic et al., 1998). Furthermore, DXR affects glucose supply and the 
ability of cells to assimilate glucose. It was demonstrated in another study that DXR inhibited the 
expression of peroxisome proliferator-activated receptor gamma (PPARγ), leading to the 
suppression of adipogenesis and resulting in the impaired import of glucose mediated through 
glucose transporter type 4 (GLUT4) (Arunachalam et al., 2013). On the other hand, MLT was shown 
to completely restore the expression of the GLUT4 gene, which was suppressed via reactive oxygen 
species (ROS)-mediated down-regulation of metabolic genes (Ghosh et al., 2007). 
Another factor limiting glycolytic flux in the DXR-challenged heart can be the result of impaired 
activity of phosphofructokinase (PFK), which is a key regulator of glycolysis. This was observed in 
studies on cardiomyocytes exposed to DXR, which caused a rapid decrease in mRNA levels of PFK 
(Bordoni et al., 1999; Iliskovic et al., 1998). These findings clearly demonstrate that DXR challenges 
the heart to sustain cellular energy production by increasing glycolysis as a way of compensating for 
the depleted energy stores in the heart. Interestingly, the expression of SIRT3 increases under these 
adverse cardiac conditions to compensate for the loss of ATP by regulating free fatty acid 
metabolism to meet the high ATP demand in the heart (Ingwall et al., 2009; Pillai et al., 2010). MLT 
has been shown to prevent an energetic shift to glycolysis in colonic smooth muscle cells from aged 
rat (Martin-Cano et al., 2014). However, it remains to be investigated what the effect of MLT is on 
the changes in metabolic substrate utilization during DXR-induced cardiotoxicity, and whether MLT 
could favourably modulate SIRT3 activity in this setting, and thus have therapeutic potential. The 
effects of MLT during DXR-induced bioenergetic failure are summarized in Figure 1.1.  
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Figure 1.1: The effect of MLT on DXR-induced bioenergetic failure. The figure illustrates the effect of DXR 
and MLT on mitochondrial respiration, ATP production, as well as glucose and fatty acid metabolism. The 
question mark (?) represents potential areas that require further investigation. Abbreviations- MLT: melatonin; 
DXR: doxorubicin; Glut 4: glucose transporter type 4; PPARγ: peroxisome proliferator-activated receptor 
gamma; PFK: phosphofructokinase; TCA: tricarboxylic acid; FA-CoA: fatty acyl-coenzyme A; CPT I and II: 
carnitine palmitoyltransferase I and II; ETC: electron transport chain; Com I, II, II, IV, and V represent 
mitochondrial electron transport chain complexes; ATP: adenosine triphosphate; ADP: adenosine 
diphosphate; Pi: inorganic phosphate; NAD: nicotinamide adenine dinucleotide; NADH: dihydronicotinamide 
adenine dinucleotide; FADH: flavin adenine dinucleotide; PCr: phosphocreatine; Cr: creatine; Mi-CK: 
mitochondrial creatine kinase bound to the inner mitochondrial membrane; SIRT3: sirtuin 3.  
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1.4 The role of melatonin in doxorubicin-induced free radical generation 
One major and widely investigated hypothesis of DXR-induced cardiotoxicity is based on the 
generation of free radicals, which induces oxidative stress (Olson et al., 1981). Reports as early as 
the mid-1970s reported that quinone-containing chemotherapeutic drugs, also known as 
anthracyclines, such as DXR, produced free radicals. This effect was first observed in rat liver 
specimens (Bachur et al., 1978). The heart, in particular, is highly susceptible to DXR-induced 
oxidative damage as it is abundant in mitochondria, which are both sources and targets for ROS 
(Doroshaw, 1983). Furthermore, the heart has an elevated rate of oxygen consumption and limited 
antioxidant defense systems when compared to other tissues (Kaiserova et al., 2007; Quiles et al., 
2002). It was demonstrated in other studies that cardiomyocytes expressed low levels of catalase 
and that antioxidant selenium-dependent GSH-peroxidase-1 was inactivated when exposed to DXR, 
which subsequently decreased cytosolic antioxidant Cu–Zn superoxide dismutase (Doroshow et al., 
1980; Li et al., 2002). 
Doxorubicin generates free radicals primarily in two ways: (i) through utilizing cellular 
oxidoreductases (NADH and NADH dehydrogenase of complex I, NADPH and cytochrome P-450 
reductases or endothelial nitric oxide synthase); and (ii) by forming complexes with iron (Tokarska-
Schlattner et al., 2006; Doroshow et al., 1980; Minotti et al., 1999). When DXR reacts with 
oxidoreductases, it is reduced to a semiquinone (i.e., a free radical). In the presence of oxygen, the 
semiquinone radical generates superoxide anions which may either give rise to lipids or hydrogen 
peroxides (Olson et al., 1981). As the heart is abundant in mitochondria, there is an abundance of 
the enzyme NADH dehydrogenase of mitochondrial complex I, and considering this fact, it has been 
demonstrated that the main mechanism that leads to ROS formation in the heart is via DXR redox 
cycling utilizing this enzyme (Wallace, 2003). This type of redox recycling can be detrimental as one 
molecule of anthracyclines generates many molecules of free radicals (Olson and Mushlin, 1990). 
Anthracycline free radicals may also form by means of an enzyme-independent mechanism, 
involving its interaction with iron. Although very little iron is available in myocytes, it has been 
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reported that DXR has the ability to extract iron from ferritin, a bound form of iron, and thus may also 
contribute to free radical production (Zweier et al., 1988). 
The general clinical approach to combating DXR-induced ROS generation in the heart involves the 
utilization of various antioxidants. This approach was strengthened by various experiments that 
yielded positive results when employing antioxidants (Yen et al., 1996; Quiles et al., 2002; 
Spallarossa et al., 2004). Although antioxidants show promising results, it is apparent that protection 
against DXR-induced cardiotoxicity in animal models seldom yields the same response in humans. 
In view of this clinical impediment, ample evidence strongly supports MLT to be one of the essential 
components to enhance an organism’s antioxidant defense system and its antioxidative effect in 
combating DXR-induced cardiotoxicity (Reiter et al., 2002). The binding of DXR to cardiolipin seems 
to initiate the disastrous cascade of events leading to free radical generation. This subsequently 
allows for DXR to inhibit complex I and generate free radicals (Doroshow and Davies, 1986; Davies 
and Doroshow, 1986). These free radicals induce further lipid peroxidation of cardiolipin and 
membranes and damage DNA, which can lead to mutations, re-arrangements, and transcriptional 
errors that impair important mitochondrial components such as that of the mitochondrial respiratory 
chain. This leads to more oxidative stress, generating a vicious cycle which culminates in 
cardiomyocyte cell death (Olson and Mushlin, 1990; Minotti et al., 2004; Ogura et al., 1991). As the 
number of injured mitochondria increase, cardiac functioning is severely compromised. 
In addition, DXR reduces or inhibits the activity of the cells antioxidant defense system (Doroshow 
et al., 1980; Li et al., 2002). MLT can effectively combat these events leading to mitochondrial 
dysfunction by increasing the expression and activity of the mitochondrial respiration chain 
complexes (complex I and IV), thereby increasing ATP production (Reiter et al., 2000). It acts as a 
potent free radical scavenger and possesses antioxidative potential (Reiter et al., 2000; Matuszak et 
al., 1997; Galano et al., 2011). Hydrogen transfer and electron transfer are known to be the main 
mechanisms that determine the free radical-scavenging activity of MLT (Galano et al., 2011). MLT 
reacts intensely with various radicals and prevents the lipid peroxidation of biological membranes 
(Galano et al., 2011). It has been proposed that MLT prevents lipid peroxidation by scavenging more 
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reactive species, such as hydroxyl radicals, rather than scavenging peroxyl radicals (Galano et al., 
2011). 
One of the most appealing and unique properties of MLT, which other antioxidants do not possess, 
is that its metabolites also exhibit antioxidant activity by scavenging ROS and reactive nitrogen 
species (RNS) (Galano et al., 2011, Galano et al., 2013). MLT and its metabolites generate a free 
radical scavenging cascade which makes MLT highly effective even at low concentrations and allows 
for continuous protection against free radical-induced damage (Galano et al., 2013). N1-acetyl-N2-
formyl-5-methoxykynuramine (AFMK) is an example of such a metabolite and is formed when MLT 
scavenges free radicals (Tan et al., 2000; Galano et al., 2011; Galano et al., 2013; Tan et al., 2001; 
Rozov et al., 2004). Another metabolite, N [1]-acetyl-5-methoxykynuramine (AMK), is formed by 
deformylation of AFMK. Both these metabolites elicit protective effects against oxidative damage 
(Galano et al., 2013); AFMK has been found to reduce lipid peroxidation and oxidative DNA damage; 
it can efficiently scavenge hydroxyl radicals and prevent cellular injury caused by hydrogen peroxide 
(Tan et al., 2000; Galano et al., 2011; Galano et al., 2013; Tan et al., 2001; Rozov et al., 2004). 
AMK, on the other hand, is a potent singlet oxygen scavenger, which deactivates a wide variety of 
ROS and RNS and also other oxidants (Galano et al., 2013). 
Another key metabolite, cyclic 3-hydroxymelatonin (C3-HOM), is formed as an immediate product of 
MLT’s interaction with reactive oxygen species (Galano et al., 2014; Tan et al., 2014). This 
metabolite has been shown to react much faster in aqueous solution than MLT, AMK and AFMK, 
and is more effective at scavenging peroxyl radicals (Tan et al., 2014). This recently identified 
metabolite of MLT not only reduces oxidative stress via its free radical scavenging cascade, but also 
plays a critical role in peroxyl radical scavenging (Galano et al., 2014). Furthermore, C3-HOM has 
been shown to protect mitochondrial cytochrome c from free radical-induced damage, and thus, it is 
likely to inhibit cellular apoptosis induced by the release of oxidized cytochrome c from mitochondria 
(Tan et al., 2014).  
MLT in turn acts to increase an organisms antioxidant defense system as both physiological and 
pharmacological doses of MLT have resulted in increased gene expression and activities of various 
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cellular antioxidants (GPx, GRd, SOD and CAT) (Reiter et al., 2000; Antolin et al., 1996; Pablo et 
al., 1998; Rodriguez et al., 2004; Fischer et al., 2013) and MLT promotes the de novo synthesis of 
glutathione (GSH) by stimulating the activity of its rate-limiting enzyme, g-glut-amyl-cysteine 
synthetase (Urata et al., 1999). Additionally, an indirect antioxidant action of MLT includes the 
inhibition of the production of nitric oxide synthase (NOS) at the level of NOS gene transcription 
(Jimenez-Ortega et al., 2009; Pozo et al., 1997). Furthermore, MLT was also shown to selectively 
inhibit increased levels of mitochondrial-inducible nitric oxide synthase (i-mtNOS) in cardiac 
mitochondria, thereby improving cardiac mitochondrial function during sepsis (Ortiz et al., 2014). 
MLT’s actions successfully stimulate a cascade of antioxidant activity, and this has likely contributed 
to its success in mitigating DXR-induced free radical generation, thereby preventing lipid 
peroxidation and improving mitochondrial and cardiac function (Liu et al., 2002; Xua et al., 2001; 
Balli et al., 2004). Of further value in the context of free radical regeneration is the ability of SIRT3 to 
prevent a cardiac hypertrophic response by scavenging cellular ROS (Sack, 2011; Scher MB et al., 
2007; Sundaresan et al., 2010). Furthermore, SIRT3 transgenic mice had increased levels of both 
MnSOD and catalase, suggesting that SIRT3 is partly responsible for the increase in antioxidant 
defense mechanisms in the heart (Scher MB et al., 2007). The use of MLT as a potent antioxidant 
drug against high levels of oxidative stress during DXR-induced cardiotoxicity has been well 
established and is greatly beneficial (Reiter et al., 2002). However, considering the role that SIRT3 
plays in this context, it would be of further benefit to this field to investigate the effect of MLT on 
mitochondrial SIRT3. The effects of MLT during DXR-induced free radical generation are 
summarized in Figure 1.2. 
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Figure 1.2: The effect of MLT on DXR-induced free radical generation. The figure illustrates how DXR 
generates ROS, how both ROS and DXR damage mitochondrial DNA, proteins and the ETC, as well as how 
MLT elicits its beneficial antioxidant effects. The question mark (?) represents potential areas that require 
further investigation. Abbreviations- MLT: melatonin; DXR: doxorubicin; DXR SQ: doxorubicin-semiquinone; 
ROS: reactive oxygen species; mtDNA: mitochondrial deoxyribonucleic acid; ETC: electron transport chain; 
ATP: adenosine triphosphate; ADP: adenosine diphosphate; Pi: inorganic phosphate; NAD: nicotinamide 
adenine dinucleotide; NADH: dihydronicotinamide adenine dinucleotide; FADH: flavin adenine dinucleotide; 
AFMK: formyl-5-methoxykynuramine; GPx: glutathione peroxidase; GRd: glutathione reductase; SOD: 
superoxide dismutase; CAT: catalase; SIRT3: sirtuin 3. 
 
1.5 The role of MLT on doxorubicin-induced cardiomyocyte cell death 
The hypothesis that DXR-induced cardiotoxicity terminates in the loss of cardiac myocytes via 
several cell death pathways has caused this mechanism to be explored at many levels. As cell death 
is central to this clinical limitation, then the underlying mechanisms involved are worth investigating, 
as this would result in novel cardioprotective strategies. Mitochondrial dysfunction is indeed a 
hallmark of DXR-induced cardiotoxicity, and during the last decade, evidence has accumulated to 
support the critical role of mitochondria in determining the fate of cardiomyocytes. There are three 
general mechanisms that implicate mitochondria as the central executioners of the intrinsic apoptotic 
pathway, necrosis and autophagic cell death during DXR-induced cardiotoxicity: (i) disruption of the 
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ETC, OXPHOS, and ATP production; (ii) release of proteins that trigger the activation of the caspase 
family of proteases; and (iii) alterations in redox potential (Green et al., 1998; Sainz et al., 2003). 
Apoptosis is initiated from two canonical signaling pathways: the extrinsic and intrinsic pathways. 
The extrinsic pathway involves the binding of death ligands (FasL, TNF-α, TRAIL) to receptors which 
subsequently recruit and activate caspase 8 and downstream effector caspase 3 (Ashkenazi and 
Dixit, 1999). The intrinsic pathway is strictly regulated by the Bcl-2 family of proteins namely the anti-
apoptotic members Bcl-2, Bcl-xL, the pro-apoptotic members Bax and Bak, and the BH3-only 
proteins such as Bad, Bid, Nix, and BNIP3 that enhance apoptosis via inhibition of Bcl-2 proteins or 
activation of pro-apoptotic Bax and Bak. Activation of BH3-only proteins further induces a cascade 
of events that release cytochrome c from the mitochondria, resulting in apoptotic cell death (Kroemer, 
and Reed, 2000). 
Studies investigating the protective role of MLT during DXR-induced cardiotoxicity have yielded 
positive results, indicating the promising nature of this pineal hormone. Liu and colleagues (2002) 
found that MLT dramatically improved survival rates in tumor-bearing mice treated with acute high 
doses of DXR and that MLT was able to attenuate the acute effects of DXR-induced functional 
changes in mouse hearts. This cardioprotective effect of MLT was attributed in part to the 
suppression of DXR-induced cardiomyocyte apoptosis via the prevention of DNA fragmentation. It 
was further demonstrated in this study that MLT exerts its cardioprotective effects without influencing 
the antitumor activity of DXR (Liu et al., 2002). This is a unique property of MLT when compared to 
other antioxidants (Sehested et al., 1993; Siveski-Iliskovic et al., 1995; Wahab et al., 2000). 
Doxorubicin is known to generate free radicals that are critical inducers of cell death. ROS causes 
damage to mitochondrial DNA (mtDNA) thus dysregulating transcriptional factors, which lead to the 
activation of the extrinsic apoptotic pathway (Zhang et al., 2009). In addition, it disturbs calcium 
homeostasis and induces lipid peroxidation which subsequently decreases mitochondrial redox 
potential and leads to the opening of the mPTP and the release of cytochrome c (Zhang et al., 2009). 
As a result of the damaging effects of increased ROS production during DXR-induced cardiotoxicity, 
many researchers have focused on assessing the potential of MLT as an antioxidant to mitigate ROS 
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production. Indeed, MLT has demonstrated that it exerts a strong anti-apoptotic effect and protects 
cardiomyocytes from ROS-induced apoptosis (Kim et al., 2005; Sahna et al., 2003; Ahmed et al., 
2005; Eser et al., 2006; Matuszak et al., 1997; Galano et al., 2011; Galano et al., 2013; Rozov et al., 
2004). Furthermore, in a model of cerebral ischemia, MLT was shown to directly inhibit the opening 
of the mPTP in a dose-dependent manner, thus preventing apoptotic cell death (Andrabi et al., 2004). 
Numerous studies have shown that DXR-induced cardiomyocyte apoptosis is associated with 
increased expression and activation of the p53 tumor suppressor protein (Liu et al., 2008; L’ecuyer 
et al., 2006). DNA lesions induced by ROS or directly by DXR-induced activation of ERK1/2, followed 
by increased phosphorylation of p53, up-regulated genes such as Bax. As a result, the intrinsic 
apoptosis pathway was activated (Kim et al., 2003). The levels of key stress proteins such as ERK-
2, phosphorylated p38, HSP-70, phosphorylated p53, and c-JUN were shown to normalize after MLT 
pre-treatment in a model of ischemic heart disease (Mukherjee et al., 2012). As there is strong 
evidence supporting the role of MLT in antagonizing the mitochondrial pathway of apoptosis, it is 
suggested that further studies be conducted to fully explore its effects in models of DXR-induced 
apoptosis. 
The mPTP opening is a critical feature of DXR-induced cell death: not only can it lead to apoptotic 
cell death but if the opening of this pore is prolonged, ATP levels become totally depleted leading to 
necrotic cell death. Necrosis has been thought to be apparent at the end stages of cardiotoxicity, but 
recent findings suggest the occurrence of necroptosis, which shares common features with both 
apoptotic and necrotic cell death (Christofferson and Yuan, 2010).  
Necroptosis is caused by poly (ADP-ribose)-polymerase (PARP) hyperactivation and subsequent 
energy depletion (Yu et al., 2002) in response to extensive DNA damage and increased ROS 
production induced by DXR, and it is a caspase-independent form of cell death (Xu et al., 2010). 
Necrostatin-1 (Nec-1), a potent inhibitor of necroptosis (Degterev et al., 2005) in combination with 
an apoptotic inhibitor, has been shown to protect the heart against ischemic injury. However, such 
research remains to be explored in the context of DXR-induced cardiotoxicity. Further investigations 
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are required to determine the effects of MLT in combination with Nec-1 to mitigate necroptosis in the 
DXR-challenged heart. 
In addition, mitochondrial dynamics have been found to play an essential role in cellular function and 
apoptosis (Suen et al., 2008). This robust regulatory potential of mitochondrial structural dynamism 
is essential in ensuring that mitochondria maintain their integrity and efficiency and it is achieved by 
sustaining a balance between mitochondrial fission and fusion. These well-orchestrated processes 
lead to heterogeneous mitochondrial morphology ranging from small, roundish individual elements 
to highly connected networks and are ever changing allowing for mitochondria to adapt according to 
the changes in their cellular environment (Rambold et al., 2011). 
During optimal cellular conditions or if successful adaption to a stressful environment is achieved, 
mitochondria tend to become tubulated and form extensive networks that are characteristic of 
mitochondrial fusion (Rambold et al., 2011). This process involves the activity of fusion proteins such 
as mitofusin (Mfn) 1 and 2 and the optic atrophic protein 1 (OPA1) (Rambold et al., 2011). In contrast, 
during conditions of stress, mitochondria become small, roundish fragments that are characteristic 
of fission (Frank et al., 2001; Karbowski and Youle, 2003). Previous studies have demonstrated that 
upon induction of oxidative stress, dynamin-related protein 1 (Drp1), a protein involved in 
mitochondrial fission, translocates from the cytosol to the mitochondria to execute the mitochondrial 
division process (Frank et al., 2001). This involves hydrolyzing GTP (Karbowski and Youle, 2003), 
which dysregulates the balance between mitochondrial fusion and fission. Mitochondrial fission leads 
to cytochrome c release and activation of caspases, which can ultimately lead to cell death (Frank 
et al., 2001). 
Further supporting the relationship between mitochondrial fission and apoptosis, it was 
demonstrated that DXR-induced mitochondrial fission is associated with the upregulation of the 
proteins p-Akt, p-Erk 1/2, p-Drp1, and p-p53 (Gharanei et al., 2013). However, co-administration of 
DXR with mdivi-1, a mitochondrial fission inhibitor, prevented detrimental effects of DXR via reduced 
expression of p-Drp1 and also prevented an increase in the levels of both p53 and Erk 1/2, thus 
suggesting a role for fission inhibitors in cardioprotection. Remarkably, MLT demonstrated multiple 
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mitochondrial protective effects in a study on Alzheimer’s disease by significantly reducing ROS-
mediated mitochondrial fission, mitochondrial membrane potential depolarization, and retardation of 
mitochondrial movement to stabilize cardiolipin; thereby preventing enhanced mitochondrial-
mediated cell death (Hsiao et al., 2013). In contrast to DXR-mediated mitochondrial fission, SIRT3-
dependent activation of OPA1 contributed to the preservation of mitochondrial networking by 
favoring mitochondrial fusion and thus protected cardiomyocytes from DXR-induced cell death 
(Scher MB et al., 2007). 
Mitochondrial fission as well as the oxidative challenge posed by DXR on the heart has also been 
correlated with an increase in autophagy. Autophagy is a catabolic cellular self-degradation process, 
which is responsible for the removal of damaged organelles and proteins, and maintains energy 
homeostasis through intracellular recycling during periods of stress (Rabinowitz and White, 2010). 
Characteristic of this process is the formation of a double-membrane structure called an 
autophagosome (Xie and Klionsky, 2007; Wang and Klionsky, 2011; Yorimitsu and Klionsky, 2005). 
When mitochondria are damaged, autophagy facilitates their degradation and engulfs the 
mitochondrial fragments into autophagosomes; this selective process is referred to as mitophagy 
(Kim et al., 2007). The elimination of damaged or malfunctioning mitochondria by mitophagy is 
essential to maintain cellular homeostasis therefore autophagy may be acting as a form of protection 
in this scenario. DXR exposure can also disrupt the clearance of damaged mitochondria by 
upregulation of p53 (Hoshino et al., 2012). High cytosolic p53 levels inhibit the translocation of 
PARKIN to the mitochondrial outer membrane (Geisler et al., 2010). The highest levels of PARKIN 
protein that function to tag defective mitochondria for autophagic degradation are found in the heart 
(Geisler et al., 2010). Thus, DXR induces autophagy but simultaneously impairs mitochondrial 
clearance by mitophagy (Geisler et al., 2010). 
However, autophagy serves as a double-edged sword in the heart under conditions of stress: on the 
one hand, it serves as a significant renewal and pro-survival mechanism of cellular organelles and, 
on the other hand, if autophagy persists beyond a certain threshold, it may lead to cellular demise 
(de Meyer et al., 2009; Gustafsson et al., 2009; Terman and Brunk, 2005). Autophagy has been 
shown to be upregulated in the myocardium in response to ischemia/reperfusion (Matsui et al., 2007) 
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as well as in DXR-induced cardiotoxicity, and this finding was strongly correlated with decreased cell 
death (Sishi et al., 2013), suggesting that autophagy was protective under these conditions. In 
contrast, in a rat model of chronic DXR cardiotoxicity, it was demonstrated that increased autophagy 
contributed to a loss of cardiac myocytes and increased the pathogenesis of cardiomyopathy (Lu et 
al., 2009). It was found in this study that treatment with 3-methyladenine (3-MA), an autophagic 
inhibitor, reduced autophagy and improved cardiac function, suggesting that autophagy is 
detrimental in the case of chronic DXR-induced cardiotoxicity. 
The controversy surrounding autophagic cell death in many studies arises from the evidence which 
is lacking for a causative role of autophagy in cell death (i.e., there is cell death with autophagy but 
not by autophagy) (Liu et al., 2013). A recent study conducted by Liu and colleagues (2013) 
highlighted that selective overactivation of autophagy can cause cell death with unique 
morphological features distinct from apoptosis and necrosis. These authors coined the term ‘autosis’ 
to describe this unique form of autophagic cell death. Based on the study, they proposed that autosis 
should meet two essential criteria put forth by the Nomenclature Committee on Cell Death: (i) the 
suppression by inhibition of the autophagic pathway and (ii) the lack of features of apoptosis and 
necrosis. 
In addition, it was demonstrated that autosis can be characterized by the classical morphological 
criteria of autophagic cell death (increased autolysosomes in dying cells lacking features of apoptosis 
and necrosis), death induced in starved adherent cells and by autophagy-inducing peptides that is 
accompanied by endoplasmic reticulum (ER) dilation and stereotypic nuclear changes, involving an 
early convoluted appearance, the formation of focal concave regions of the nucleus with surrounding 
focal swelling of the perinuclear space, and the accumulation of structures within this space at early 
stages of the process (Liu et al., 2013). Moreover, autosis but not apoptosis or necrosis was shown 
to be selectively inhibited by cardiac glycosides (Liu et al., 2013). In light of the above information, it 
would be of interest to evaluate the extent to which autophagic cell death by autosis contributes to 
cardiomyocyte cell loss in the context of DXR-induced cardiotoxicity as the criteria to distinguish this 
form of cell death from others are now available. 
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Although the role of MLT in the regulation of autophagy and mitophagy was highlighted in a recent 
review (Coto-Montes et al., 2012), the effect of MLT on autophagy and mitophagy during DXR-
induced cardiotoxicity remains to be elucidated. Only recently Kang et al. (2014) demonstrated, using 
a model of liver ischemia/reperfusion (I/R) injury, that autophagic flux was increased in response to 
I/ R injury, but this was attenuated by MLT via inhibiting mammalian target of rapamycin (mTOR)-
dependent autophagy (Kang et al., 2014). However, it is unclear to what extent MLT activates 
mTOR-dependent or mTOR-independent pathways. The suppression of autophagy by MLT 
suggested its protective role during I/R injury (Kang et al., 2014). It seems possible that MLT could 
also potentially suppress the increase in autophagic flux observed during DXR-induced 
cardiotoxicity; however, this aspect would have to be investigated. The effects of MLT and DXR on 
apoptosis, necrosis, necroptosis, autophagy, mitophagy, and mitochondrial fission and fusion during 
DXR-induced cardiotoxicity are summarized in Figure 1.3. 
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Figure 1.3: The effect of MLT and DXR on cardiomyocyte cell death. Mechanisms of cell death include 
apoptosis, necroptosis, necrosis, and autophagy. The question mark (?) represents potential areas that require 
further investigation. Abbreviations: MLT: melatonin; DXR: doxorubicin; ROS: reactive oxygen species; 
mtDNA: mitochondrial deoxyribonucleic acid; MPTP: mitochondrial permeability transition pore; PARP: poly 
[ADP-ribose] polymerase; cyt c: cytochrome complex; ERK1/2: extracellular signal-regulated kinases 1/2; p-
p53: phospho-tumor protein 53; Drp1: dynamin-related protein 1; Fis1: mitochondrial fission 1 protein; OPA1: 
optic atrophy protein 1; Mfn: mitofusin; BAX: apoptosis regulator protein/B-cell lymphoma 2-like protein 4; 
Fas/FasL: apoptosis-stimulating fragment/apoptosis-stimulating fragment ligand; SIRT3: sirtuin 3. 
 
1.6 Motivation  
Despite advances in medical technology, surgical approaches and the discovery of novel drugs in 
the current era, chemotherapy remains a major breakthrough in combating cancer and has been 
shown to significantly increase the survival rate of cancer patients. Doxorubicin (DXR) is one of the 
most effective and generally prescribed chemotherapeutic drugs for the treatment of various 
cancers. Regrettably, the eminent use of this antineoplastic agent is limited due to detrimental side 
effects such as cardiotoxicity. Abnormal mitochondrial function, damaged mitochondrial DNA, 
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decreased respiratory complex activity, increased ROS production, and augmented electron leakage 
and mPTP opening have all been shown to play crucial roles in the pathophysiology of DXR-induced 
cardiotoxicity. Mitochondrial changes are not only observed at the level of respiratory complex 
dysfunction and oxidative damage, but also in the disturbed balance between mitochondrial fusion 
and fission and defective clearance of these organelles by mitophagy, with the consequence of 
compromised cardiac function and contractility. It is therefore crucial to equally assess other 
mitochondrial parameters such as fission and fusion, mitophagy, and mitochondrial sirtuin activity. 
The key role of mitochondria in DXR-induced cardiotoxicity indicates that supporting the integrity and 
functioning of these organelles should be given priority, thereby reducing cardiomyocyte death. 
Cardiotoxicity poses a major clinical challenge to the collaborative field of cardio-oncology and a 
compelling need for novel or adjuvant therapeutic agents is needed. Melatonin (MLT), a hormone 
primarily secreted form the pineal gland may serve as such an agent. Its administration during or 
prior to chemotherapy shows great promise in this therapeutic avenue as demonstrated in various 
studies owing to its dually oncostatic and cardioprotective nature. The beneficial effects of MLT 
administration against DXR-induced cardiotoxicity are in part due to its direct free radical scavenger 
activity and its indirect antioxidant properties. An increased reporting of the effect of MLT on 
mitochondrial bioenergetics, mitochondrial fission and fusion, its action on mitochondrial sirtuin 
activity, its role in autophagy and mitophagy and in cell death will undoubtedly provide insights that 
deepen our understanding of MLT’s protective mechanisms during DXR-induced cardiotoxicity.  
Therefore this study aimed to investigate the effect of pre-treatment with MLT during DXR-induced 
cardiotoxicity on: cell death and autophagy/mitophagy, mitochondrial ROS production, mitochondrial 
membrane potential, mitochondrial morphology, mitochondrial fission and fusion, mitochondrial 
bioenergetics and biogenesis and, sirtuin activity. We further aimed to investigate the effect of daily 
MLT administration on cardiac function and tumor growth in an in vivo tumor-bearing rat model of 
acute DXR-induced cardiotoxicity. We hypothesize that pre-treatment with MLT will stabilize 
mitochondrial function during DXR-induced cardiotoxicity which will subsequently increase 
cardiomyocyte survival and improve cardiac function whilst inhibiting tumor growth. 
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Chapter 2 
 
Materials and methods 
2.1 In vitro Study design – Phase 1 
In phase 1 of this study, the in vitro model of acute doxorubicin-induced cardiotoxicity is described. 
H9c2 rat embryonic heart-derived ventricular cells were employed and five treatment groups were 
established: (i) control; (ii) vehicle control; (iii) doxorubicin; (iv) melatonin and; (v) pre-treatment with 
melatonin followed by doxorubicin exposure. The following cellular and mitochondrial parameters 
were assessed: Cell viability and apoptosis, autophagy and mitophagy, ROS generation, 
mitochondrial membrane potential, mitochondrial morphology, mitochondrial fission and fusion, 
mitochondrial bioenergetics and biogenesis, and sirtuin activity. The methods used to assess the 
above parameters are illustrated in Figure 2.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic representation of the in vitro study design. H9c2 cells were treated as indicated 
above, and were used to assess various mitochondrial and cellular parameters. 
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2.1.2 Cell culture and maintenance of H9c2 cell line 
H9c2 rat embryonic heart-derived ventricular cells were originally obtained from the European 
Collection of Cell Cultures (ECACC No. 8809294). Cells were maintained in a monolayer at 37°C 
and in a 21% O2, 5% CO2, humidified air atmosphere of 95% and were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Invitrogen Gibco), supplemented with 10% fetal bovine serum 
(Invitrogen, Gibco) and 1% penicillin/streptomycin solution (Invitrogen, Gibco).  Cells were allowed 
to proliferate in T75 flasks (75 cm2 flasks, Nest Scientific, USA) and the growth medium was 
refreshed every 48 hours. When cultures reached 80% confluency they were sub-cultured (splitting 
of cell cultures were achieved) by washing the cell monolayer with warm (37°C) media (DMEM) 
followed by trypsinization using 0.25% Trypsin-ethylene-diaminetetra-acetic acid (trypsin-EDTA) 
(Invitrogen Gibco). Cells were gently agitated to ensure complete detachment from the flask and 
were transferred to a sterile tube for centrifugation at 1500 rpm for 3 minutes. Cell pellets were re-
suspended in fresh warm growth medium and a hemocytometer was used to count the cells. Cells 
were then seeded at the appropriate density in fresh warm growth medium for experiments or further 
passaging. Cells between passages 10 and 17 were used in all experiments. 
2.1.3 Cell culture treatments 
Upon treatment, growth medium was removed and replaced with fresh growth medium containing 
respective treatments. Additionally, cells were washed twice with warm DMEM to ensure the removal 
of debris and non-viable cells. Initially, a pilot study was performed to determine a clinically relevant 
concentration of DXR that would induce DXR-induced cardiotoxicity (Figure 3.1.1). H9c2 cardiac 
myoblasts were treated with 1, 2, 3, 4 and 5 µM of DXR for 24 hours and cell viability was assessed. 
Based on the results (Figure 3.1.1), cells treated with DXR at a concentration of 3 µM for 24 hours 
was used in all in vitro experiments. Additionally, a dose and time response study was performed to 
determine a concentration of MLT that would reduce the toxicity in H9c2 cells treated with DXR (3 
µM). Cells were pre-treated with MLT at concentrations of 10, 20 and 50 µM for either 1 or 24 hours, 
the cell culture medium was removed and thereafter cells were treated with DXR (3 µM) for 24 hours. 
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Based on the results, cells pre-treated with MLT at a concentration of 10 µM for 24 hours followed 
by DXR treatment (3 µM) for 24 hours was used in all in vitro experiments. Once the dose and time 
responses for treatments were established, five treatment groups were used for the in vitro model of 
this study as mentioned in section 2.1 (study design). 
2.1.3.1 Doxorubicin (DXR) treatment 
A stock solution of DXR (Sigma Chemical Co., St Louis, MO, US) at a concentration of 3.4 mM was 
prepared by dissolving the compound in DMEM. Upon treatment, DXR was added to fresh warm 
growth medium to achieve a final concentration of 3 µM. Flasks containing DXR treated cells were 
covered in aluminum foil as DXR is a light sensitive compound. Flasks were then incubated for 24 
hours. 
2.1.3.2 Melatonin (MLT) treatment 
A stock solution of MLT (Sigma Chemical Co., St Louis, MO, US) at a concentration of 21.5 mM was 
prepared by dissolving the compound in ethanol. Absolute ethanol (95%) was diluted with sterile 
deionized water (dH2O) to 50% prior to being used to dissolve the MLT. Upon treatment, the MLT 
stock solution was freshly prepared and was added to fresh warm growth medium to achieve a final 
concentration of 10 µM. Flasks containing MLT treated cells were covered in aluminum foil as MLT 
is a light sensitive compound. Flasks were then incubated for 24 hours. Since the MLT was dissolved 
in ethanol, a vehicle control group was initially included in cell viability experiments to assess if 
ethanol had an effect on cell viability (Figure 3.1.2). The vehicle control group was treated with 0.02% 
of ethanol. 
 
2.1.4 Cell Viability Assays 
2.1.4.1 MTT Cell Viability Assay 
The MTT cell viability assay is based on the principal of MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide, a tetrazole) (Sigma Chemical Co., St Louis, MO, US), a yellow salt, 
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which is reduced to purple formazan crystals by enzymes in the cytoplasm and in the mitochondria 
of viable cells. This reductive capacity is dependent on active mitochondrial reductase enzymes 
(dehydrogenases), thus the conversion can be directly correlated with the number of viable cells 
when assessed spectrophotometrically. Mitochondrial dehydrogenases of viable cells cleave the 
tetrazolium ring, yielding purple MTT formazan crystals which are insoluble in aqueous solutions. 
Acidified solutions such as the Isopropanol/Triton X solution can be used to dissolve the purple 
crystals. 
After the termination of the treatment, growth medium was removed from each well of a 6 well plate 
(Nest Scientific, USA) and cells were washed with warm (37°C) sterile phosphate buffered saline 
(PBS). A solution of PBS and MTT (0.01 g/ml) was added to each well. The plate was covered in 
aluminum foil and incubated at 37ºC for 1 hour. Next, if cells were detached, the contents of each 
well was transferred to brown microtubes and centrifuged at 1000 rpm for 2 minutes. The 
supernatant was decanted and 2 ml of hydrogen chloride-isopropanol/Triton (1% HCl in isopropanol; 
0.1% Triton X-100; 50:1) solution was added to each pellet and re-suspended. Some cells remained 
attached to the well, thus the re-suspension was added back into the wells, the plates were covered 
with aluminum foil and gently agitated at 37ºC for 5 minutes to dissolve the purple crystals formed. 
The contents of each well was then transferred to a 2 ml cuvette. The optical density (OD) was 
determined spectrophotometrically (Cecil-CE 2021-2000 Series, Lasec) at a wavelength of 540 nm, 
using the HCl-isopropanol/Triton X solution as a blank. All values obtained from the treated groups 
were expressed as a percentage of the control values. All MTT assays were performed in triplicate 
for each group and three independent experiments were done.  
2.1.4.2 Trypan blue cell exclusion technique 
Trypan Blue cell exclusion technique is based upon the unique properties of the chromophores 
present in this vital dye. The chromophores are negatively charged, thus only interact with cells that 
have damaged membranes (staining blue). Thus, all cells which are viable exclude the dye.  
H9c2 cells were grown and treated as previously described (section 2.1.3).  At the termination of 
treatment, growth medium was removed and cells were washed with warm (37°C) sterile PBS, 
Stellenbosch University  https://scholar.sun.ac.za
28 | P a g e  
 
trypsinised and centrifuged at 1500 rpm for 3 minutes. The supernatant was removed and the pellet 
re-suspended in 1 ml PBS. From this cell suspension 10 µl were removed and added to 10 µl of a 
0.3% Trypan Blue dye (Invitrogen, USA) and gently agitated. Of this solution, 10 µl were added to a 
two chambered cell counting slide (Invitrogen, USA). The slide was then inserted into the Countess® 
Automated Cell Counter (Invitrogen, USA) and the number of trypan blue positive and negative cells, 
and the absolute total cell number of the suspension was automatically calculated by the instrument. 
All values obtained from treated groups were expressed as a percentage of the control values. All 
assays were performed in triplicate for each group and three independent experiments were done.  
 
2.1.5 Apoptosis assay 
2.1.5.1 Caspase-Glo ® 3/7 Assay 
The Caspase-Glo ® 3/7 assay kit (Promega, G8091) provides a reagent containing a luminogenic 
caspase-3/7 substrate, which is optimized for caspase and luciferase activity. Addition of the reagent 
to the cells result in caspase mediated cleavage of the substrate, followed by the release of amino-
luciferin (a substrate for luciferase) which generates a luminescent signal. Luminescence is 
proportional to the amount of caspase activity present in the sample. 
 H9c2 cells were grown and treated, as previously stated (section 2.1.3) in a 96-well white plate. 
Caspase-3/7 reagent was added to each well (100 μl) and incubated for 1 hour at room temperature. 
Immediately after incubation, luminescence was measured using a luminometer (GloMax® 96 
microplate Luminometer, Promega). All values obtained from treated groups were expressed as a 
percentage of the control values. Three independent experiments were done with 12 replicates for 
each group for each independent experiment. 
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2.1.6 ROS generation 
ROS generation was assessed using the 2', 7’-dichlorodihydrofluorescein diacetate (H2DCFDA, 
Molecular Probes, D399) and MitoSOX Red (Molecular Probes, M7514) respectively. H2DCFDA is 
a versatile fluorescent probe since it is able to detect hydrogen peroxide (H2O2), nitrogen dioxide, 
hydroxyl radicals, and carbonate radicals in intact cells. H2DCFDA is hydrolyzed in the cytosol and 
forms a DCFH carboxylate anion. Oxidation of the DCFH carboxylate anion yields a fluorescent 
product of DCF, which is excited at 495 nm and emits fluorescence at 520 nm. MitoSOX Red is a 
fluorescent probe used to measure superoxide production in the mitochondrial matrix. Due to its 
cationic properties, MitoSOX Red is able to rapidly target the mitochondria, where it is oxidized by 
superoxide. Oxidation of MitoSOX Red yields a fluorescent product known as 2-
hydroxymitoethidium, which is excited at 510 nm and emits fluorescence at 580 nm. 
H9c2 cells were grown and treated as previously described in T25 flasks (25 cm2 flasks, Nest 
Scientific, USA).  A positive control treated with H2O2 (100 μmol/L) was included. At the termination 
of treatment, growth medium was removed and cells were washed with warm (37°C) sterile PBS. 
Cells were then trypsinized using 0.25% trypsin-EDTA and centrifuged in a 15 ml tube at 1500 rpm 
for 3 minutes. The supernatant was discarded and cells were resuspended in 500 µl warm PBS. 
DCF (50 µmol/L) and MitoSOX Red (5 μM) were added to the cell suspension and cells were gently 
resuspended to ensure an even distribution of the fluorescent probes. The cells were incubated at 
37°C for 15 minutes and analysed on the FACSAria I flow cytometer (Becton Dickinson Biosciences, 
USA). A 488 nm laser was used for laser-induced fluorescence and the fluorescent emission was 
collected between wavelength regions 510-580 nm, a minimum of 10 000 events were analyzed. 
Fluorescent intensity signal was measured using the geometric mean on the intensity histogram. 
Due to the inherent fluorescent properties of DXR which are similar to MitoSOX Red, the fluorescent 
intensity of DXR was measured and subtracted from cells treated with DXR and stained with 
MitoSOX Red. All values obtained from treated groups were expressed as a percentage of the 
control values. Atleast three independent experiments were done with duplicates for each group for 
each independent experiment. 
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2.1.7 Mitochondrial Membrane Potential Analysis 
Differences in mitochondrial membrane potential were detected by using 5, 5’, 6, 6’,-tetrachloro-1, 
1’, 3, 3’,-tetraethylbenzimidazolylcarbocyanine (JC-1) (Invitrogen, T3168). JC-1 is a ratiometric 
(red/green), cationic, lipophilic fluorescence probe. Due to its cationic nature, JC-1 easily enters the 
mitochondria and forms aggregates (J-aggregates) that emit red fluorescence in the phycoerthrin 
(PE - red) channel. However, in cells with decreased mitochondrial membrane potential or 
depolarized mitochondria, JC-1 remains in the cytoplasm in its monomeric form, which emits green 
fluorescence in the fluorescein (FITC - green) channel. Since the monomers and aggregates of JC-
1 have different emission spectra, changes in mitochondrial membrane potential can be assessed 
by comparing the ratio of PE to FITC (red/green). Therefore, the ratio of red/green decreases as the 
mitochondrial membrane potential decreases. 
H9c2 cells were grown and treated as previously described in T25 flasks (25 cm2 flasks, Nest 
Scientific, USA).  A positive control treated with Carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP) (1 µM) was also included. At the termination of treatment, growth medium was removed and 
cells were washed with warm (37°C) sterile PBS. Cells were then trypsinized using 0.25% trypsin-
EDTA and then centrifuged in 15 ml tube at 1500 rpm for 3 minutes. The supernatant was discarded 
and the cells were resuspended in 500 µl of warm PBS. JC-1 (5 µM) was added to the cell 
suspension and cells were gently resuspended to ensure an even distribution of the fluorescent 
probe. The cells were incubated at 37°C for 20 minutes and analysed on the FACSAria I flow 
cytometer (Becton Dickinson Biosciences, USA). A 488 nm laser was used for laser-induced 
fluorescence and the fluorescence emission was collected between wavelength regions 515-545 nm 
and 575-625 nm, a minimum of 10 000 events were analyzed.  The fluorescence intensity signal was 
measured using the geometric mean on the intensity histogram. All values obtained from treated 
groups were expressed as a percentage of the control values. Atleast three independent 
experiments were done with duplicates for each group for each independent experiment. 
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2.1.8 Mitochondrial Network Analysis 
2.1.8.1 Live Cell Imaging  
Assessment of the mitochondrial network was performed using live cell imaging. H9c2 cells were 
seeded at a density of 20x103 cells in eight-well chamber coverglass slides (Nunc, Denmark) and 
treated as previously described.  At the termination of treatment, growth medium was removed and 
warm fresh growth medium containing Tetramethylrhodamine, Ethyl Ester, Perchlorate (TMRE) 
(1:1000, Molecular Probes, T669) and Hoechst 33342 (1:200, ThermoScientific, 62249) was added 
to each well to stain for the mitochondrial network (red) and the nucleus (blue) respectively. The 
Olympus Cell ® system attached to an IX 81 inverted fluorescence microscope fitted with an F-view-
II cooled CCD camera (Soft Imaging Systems) was used to observe cells which were maintained at 
37°C during the imaging process. Images were acquired through an Olympus Plan Apo N60x/1.4 Oil 
objective lens. The mitochondrial network was imaged through excitation of TMRE using a 572 nm 
excitation filter and the nucleus was imaged through excitation of Hoechst 33342 using a 360 nm 
excitation filter. Emission was collected using a UBG triple bandpass emission filter. Cell^R software 
was then used to process the acquired images.  
2.1.8.2 Mitochondrial Network and Morphology assessment 
A morphometric network assessment of the mitochondria was conducted on processed images as 
previously described by Mortiboys et al. (2008), using ImageJ (version 1.42) software. The 
mitochondrial parameters assessed included the mitochondrial aspect ratio and the form factor. The 
mitochondrial aspect ratio is the ratio between the major and minor axes of the ellipse equivalent to 
each mitochondrion and, the form factor or degree of branching is defined by the equation 
Pm2/4πAm, where Pm is the perimeter or length of the mitochondrial outline and Am is the area of 
the mitochondrion. Four independent experiments were conducted and a minimum of 50 images 
were processed for each experimental group.  
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2.1.9 Mitochondrial Bioenergetics 
2.1.9.1 Cellular ATP Analysis 
Cellular ATP levels were quantified using the Enliten ATP assay kit (Promega, FF2000). H9c2 cells 
were grown and treated as previously described (section 2.1.3) in T25 flasks (25 cm2 flasks, Nest 
Scientific, USA). At the termination of treatment, growth medium was transferred to sterile 2 ml 
microtubes and centrifuged at 1500 rpm for 3 minutes to ensure that detached cells were also 
included for ATP analysis. Adherent cells were then trypsinized using 0.25% trypsin-EDTA and then 
centrifuged in 2 ml microtubes at 1500 rpm for 3 minutes. The supernatant was discarded and cells 
were resuspended in growth medium (DMEM). The cells were then centrifuged at 10 000 rpm for 3 
minutes at 4°C, the supernatant was discarded and the pellet was resuspended  in 50 µl ice cold 
lysis buffer (pH 7.75)  containing 2-Amino-2-(hydroxymethyl)-1,3-propanediol hydrochloride (Tris-
HCl ,100 mM) and Ethylenediaminetetraacetic acid (EDTA, 4 mM) as previously described (Essman 
et al., 2003). The lysis buffer was boiled and added (150 µl) to the cell suspension which was 
maintained at 99°C for 2 minutes in a water bath. The cells were then centrifuged at 10 000 rpm for 
3 minutes at 4°C. The supernatant containing cellular ATP was collected in 2 ml sterile microtubes 
and stored at -80 °C until further analysis. Samples were obtained from four independent 
experiments. The samples (50 μl) and rL/L reagent (50 μl, Enliten ATP assay, Promega, FF2000) 
were added to a 96-well luminometer white plate. In addition, a standard curve was produced 
according to the manufacturer’s protocol that was later used to calculate the concentration of cellular 
ATP contained in each sample which was normalized to the amount of protein present in each 
sample and expressed as nM of ATP per µg of protein. Luminescence was measured using a 
luminometer (GloMax® 96 microplate Luminometer, Promega). 
2.1.9.2 Mitochondrial Respiration Analysis 
Mitochondrial respiration was measured in intact H9c2 cells using the Seahorse XF96 Cell Mito 
Stress Test Kit (Seahorse Biosciences, USA), according to the manufacturer’s instructions. Cells 
were seeded into a 96-well XF Analyser Cell Culture Plate at an optimized density of 7x103 cells per 
well and were incubated overnight at 37°C. Cells were then treated as previously described. At 
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termination of treatment, cells were washed and refreshed with 175 µl of XF Assay Medium (DMEM 
containing 2 mM of L-glutamine supplemented with 5 mM glucose and 1 mM sodium pyruvate), and 
placed into a CO2 - free incubator at 37°C for 1 h. Thereafter, the oxygen consumption rate (OCR) 
was measured in each well using the Seahorse XFe 96 Extracellular Flux Analyzer (Seahorse 
Biosciences, USA) and the XFe Wave software (Seahorse Biosciences, USA).  
The Seahorse assay is based upon the fluorimetric detection of O2 and H+ levels by using probes on 
a sensor cartridge which is attached to the a 96-well XF Analyser Cell Culture Plate. After each 
recorded measurement, the sensor cartridge rises which allows for the re-oxygenation of media 
through mechanical mixing thus making it possible for repeated O2 and pH measurements to be 
recorded in real time. The sensor cartridge is equipped with four drug-delivery injection ports which 
were loaded with 25 µl of: oligomycin (a complex V inhibitor), carbonyl cyanide p-
trifluoromethoxyphenyl hydrazine (FCCP, a protonophore which collapses the inner membrane 
gradient, causing the ETC to function at its maximal rate), rotenone and antimycin A (complex I and 
III inhibitors respectively which are used to shut down the ETC completely). Three cycles of  OCR 
measurements were performed for each well, consisting of basal OCR measurements, OCR 
measurements following the injection of 1 µM oligomycin, OCR measurements following the injection 
of 1 µM carbonyl cyanide p-trifluoromethoxyphenyl hydrazone (FCCP), and OCR measurements 
following the simultaneous injection of 1 µM rotenone and 1 µM antimycin A. Each cycle consisted 
of a 3 minute recorded measurement following 3 minutes of re-oxygenation of media through 
mechanical mixing. Non-mitochondrial respiration was assessed by measuring OCR after complete 
inhibition of the ETC with rotenone and antimycin A and this rate was subtracted from all other 
measurements in order to obtain the OCR by the mitochondria.  
Four parameters of OCR were calculated as follows: (i) Basal Respiration Rate (BRR) was calculated 
by subtracting non-mitochondrial respiration from the baseline OCR, (ii) ATP- linked respiration 
which was calculated by subtracting the oligomycin OCR rate from the BRR, (iii) Electron Transport 
System Capacity (ETS) was calculated by subtracting non-mitochondrial respiration from the FCCP 
OCR, (iv) Mitochondrial Spare Respiratory Capacity (MSRC) was calculated by subtracting the BRR 
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from the MRC. All OCR measurements were expressed as pmol O2 per minute and normalized to 
cell number using the CyQUANT Cell proliferation kit (Invitrogen, USA). The CyQUANT assay is 
based on a fluorochrome binding to nucleic acids and therefore measures the relative DNA content 
in each well of the plate. The fluorescence was measured in a microplate luminometer with an 
excitation wavelength of 485 nm and an emission wavelength of 530 nm. Respiration parameters 
were calculated during one independent experiment based on an average of each replicate per 
measurement (no. of replicates=12). Measurements were performed three times for each replicate. 
 
2.1.10 Immunoblot Analysis 
2.1.10.1 Whole Cell Protein Extraction  
H9c2 cells were grown and treated as previously described in T25 flasks (25 cm2 flasks, Nest 
Scientific, USA). At the termination of treatment, growth medium was removed and cells were 
washed with cold PBS (4°C). Proteins were extracted from cells by adding 500 µl of cold 
Radioimmunoprecipitation assay (RIPA) buffer, pH 7.4, containing: Tris-HCL (2.5 mM), EDTA (1 
mM), Sodium Fluoride (NaF, 50 mM), Sodium orthovanadate (Na3VO4, 1 mM), soybean trypsin 
inhibitor (SBTI, 4 μg/ml), phenyl-methyl-sulphonyl fluoride (PMSF, 0.1 mM), Leupeptin (10 mg/ml), 
Benzamidine (1 mM),  Nonidet-P40 (NP-40, 1%) and, Sodium Deoxycholate (NADC, 0.5%). Cells 
were then gently scraped from the bottom of culture flasks using a sterile cell scraper whilst 
maintained on ice. The contents of each flask was then transferred to pre-chilled 2 ml Eppendorf 
tube followed by sonication at 15% amplitude for 10 seconds using the Misonic Ultrasound Liquid 
Processor (Qsonica, USA). Sonication of cells was performed to ensure the release of cellular 
proteins by lysing the cell membrane. Cell lysates were then centrifuged at 8000 rpm for 10 minutes 
at 4°C, the supernatant was transferred into pre-chilled microtubes and stored at -80°C until further 
use. Protein lysates were obtained for each group from four independent experiments. 
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2.1.10.2 Mitochondrial Isolation from cells and Protein Extraction  
Mitochondrial isolation from cultured cells was performed using the Mitochondrial Isolation Kit for 
Cultured cells (Abcam, ab110170) according to the manufacturer’s instructions. H9c2 cells were 
grown and treated as previously described in T25 flasks (25 cm2 flasks, Nest Scientific, USA). At the 
termination of treatment, growth medium was removed and cells were washed with cold PBS (4°C). 
Proteins were extracted from cells by adding 500 µl of cold Radioimmunoprecipitation assay (RIPA) 
buffer. Cells were then gently scrapped from the bottom of culture flasks using a sterile cell scraper 
whilst maintained on ice. The contents of each flask was then transferred to pre-chilled 2 ml 
microtubes and was stored at -80°C overnight. Samples were then thawed in order to weaken the 
cell membranes and resuspended in 5 mg/ml of Reagent A (Abcam, ab110170) followed by 
incubation on ice for 10 minutes. Cells were transferred to a pre-cooled Dounce Homogenizer and 
mechanically homogenized using 30 dounce strokes with a pestle. The homogenate was then 
transferred to 2 ml microtubes and centrifuged at 2000 rpm for 10 minutes at 4°C. The supernatant 
#1 was transferred to a pre-cooled 2 ml Eppendorf tube and maintained on ice and the pellet was 
resuspended in 5 mg/ml of Reagent B (Abcam, ab110170). The homogenization and centrifugation 
at 2000 rpm for 10 minutes at 4°C was then repeated and supernatant #2 was combined with 
supernatant #1, the pellet was discarded. The combined supernatants (#1 and #2) were then mixed 
thoroughly and centrifuged at 8000 rpm for 15 minutes at 4°C. The supernatant was discarded and 
the pellet was resuspended in 500 µl of Reagent C (Abcam, ab110170) supplemented with protease 
inhibitors. The mitochondrial lysates were then stored at -80°C until further use. Mitochondrial lysates 
were obtained for each group from four independent experiments. 
2.1.10.3 Protein Determination and Sample Preparation 
Cellular and mitochondrial protein content was quantified using the Direct Detect® FTIR 
Spectrometer (Merck Millipore, USA). The Direct Detect ® protein quantification method is based on 
the principal of using Infrared Spectroscopy where infrared light interacts with a molecule that 
absorbs radiation at specific frequencies depending on its structure.  Mitochondrial, protein lysates 
and RIPA buffer that was used to extract proteins, were thawed whilst maintained on ice. Cartridge 
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cards containing four slots were then loaded with 2 μl of each sample (slots 2 - 4), 2 μl of RIPA buffer 
was added to the first slot on each new card as it served as the blank. The card was then inserted 
into the instrument, which then initiated an automated drying cycle of the samples. The protein 
content was measured in each sample in μg/ml. Protein samples at a concentration of 20 μg/ml were 
prepared using a combination of β-Mercaptoethanol (150 μl) and Laemmli sample buffer (850 μl). 
Samples were then stored at - 80°C until further use. 
2.1.10.4 Sodium Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)                    
and Electrotransfer 
Proteins were loaded and separated using gradient polyacrylamide gels with a 4% stacking gel (4 – 
20% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Bio-Rad). A BLUeye pre-stained protein 
ladder (GeneDirex, PM007-0500) was loaded in the first lane on each gel for determination of 
molecular weights of specific bands. Protein samples were boiled for 5 min at 95˚C and briefly 
centrifuged before loading each sample (20 μg/ml) into the remaining gel lanes. Proteins were 
separated by SDS-PAGE (Criterion-PROTEAN® Tetra cell, Bio-Rad) at a constant voltage of 100 V 
and current of 400 mA for 10 minutes and thereafter at a constant voltage of 150 V for 60 minutes 
(Power Pac 1000, Bio-Rad). Following SDS-PAGE, the stain-free gels were imaged using the 
ChemiDoc™ XRS + System (Bio-Rad) to ensure equal loading. The proteins were then transferred 
to a polyvinylidine fluoride (PVDF) membrane (Trans-Blot® midi transfer pack, Bio-Rad) at a 
constant voltage of 12 V for 12 minutes using the Trans-Blot Turbo System (Bio-Rad). The PVDF 
membranes were imaged using the ChemiDoc™ XRS + System (Bio-Rad).  
2.1.10.5 Immuno-detection 
Non-specific binding sites were blocked with 5% fat-free milk in TRIS-buffered saline-Tween (TBS-
T) for 2 hours and membranes were incubated overnight at 4°C with the primary antibodies diluted 
in TBS-T. The following proteins were detected using the cellular protein lysates: cleaved caspase-
3, cleaved Poly (ADP-ribose) polymerase (cleaved PARP), Microtubule-associated proteins 1B light 
chain 3 (LC3), Sequestosome 1 (SQSTM1/p62), Sirtuin 1 (SIRT1), Peroxisome proliferator-activated 
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receptor gamma coactivator 1-alpha (PGC-1α) and Beta-actin (β-actin). The mitochondrial protein 
lysates were used to detect the following proteins: Dynamin-related protein 1 (Drp1), Fission 1 
protein (hFis1), Optic Atrophy 1 (OPA1), Mitofusin 1 (Mfn1), Mitofusin 2 (Mfn2), PTEN-induced 
putative kinase 1 (Pink1), Parkinson protein (PARKIN), Sirtuin 3 (SIRT3) and Translocase of outer 
mitochondrial membrane 20 (TOM20). Following overnight incubation, membranes were washed in 
TBS-T (3 x 5 minutes) and the primary antibody was conjugated by the addition of a diluted 
horseradish peroxidase-labeled secondary antibody for 1 hour at room temperature. Thereafter, 
membranes were thoroughly washed before being incubated with Clarity™ Western ECL Substrate 
(Bio-Rad). Membranes were then exposed with the ChemiDoc™ XRS + System (Bio-Rad). Protein 
bands were quantified using Image Lab™ Software (Bio-Rad). 
 
2.1.11 Statistical Analysis 
Values are expressed as mean ± standard error of the mean (SEM). Analysis of data was conducted 
using GraphPad Prism, version 5.0 (GraphPad Inc.). One-way Analysis of Variance (ANOVA) with 
Bonferroni’s Multiple Comparison as a post-hoc test was used to assess the statistical significance 
between treatment groups. Values of p<0.05 were considered significant. 
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2.2 In vivo Study design – Phase 2 
Phase 2 of this study, describes an in vivo tumor-bearing rat model of acute doxorubicin-induced 
cardiotoxicity. Female Sprague Dawley rats were randomly allocated to the following groups: (i): 
control (CTRL); (ii): tumor control (T CTRL); (iii): vehicle control (V CTRL); (iv): doxorubicin (DXR); 
(v): melatonin (MLT) and; (vi): doxorubicin and melatonin (DXR+MLT). Briefly, at the age of sixteen 
weeks, all rats, except the control group, were inoculated with LA7 rat tumor cells. The DXR group 
received 4 mg/kg of DXR on days 4, 8 and 12, the MLT group received 6 mg/kg of MLT in their 
drinking water daily and, the DXR+MLT group received both DXR and MLT.  The study was 
terminated after 14 days and rat hearts were rapidly excised to perform isolated rat heart perfusions. 
The perfused heart tissues were then used for immunoblot analysis. A schematic representation of 
the study design is provided in Figure 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Schematic representation of in vivo study design. Female Sprague Dawley rats were 
inoculated with LA7 rat tumor cells. Animals were treated with 4 mg/kg of DXR and daily with 6 mg/kg of MLT. 
Rat hearts were used to conduct isolated heart perfusions whereafter, rat heart tissues were freeze-clamped 
and stored at -80°C until further analysis. 
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2.2.1 Animal care and grouping 
Female Sprague Dawley rats were obtained from the University of Stellenbosch Central Research 
Facility. Upon receiving animals between 8 – 10 weeks of age, animals were randomly grouped in 
cages. Animals were allowed to acclimatize to the environment for ± 6 weeks prior to the 
commencement of this study and were housed with free access to water and food, a 12-h dark/light 
cycle (light from 6:00 a.m. to 6:00 p.m.) with temperature  and humidity kept constant at 22ºC and 
40%, respectively. The experimental procedures were conducted according to the guidelines for the 
care and use of laboratory animals implemented at Stellenbosch University and were approved by 
the Committee for Ethical Animal Research of the Faculty of Health Sciences, University of 
Stellenbosch (Ethical clearance: SU-ACUM13-00015).  
 
2.2.2 Cell culture and maintenance of LA7 cell line 
LA7 rat mammary adenocarcinoma-derived tumor cells (ATCC No CRL2283) were a kind gift from 
Dr Annadie Krygsman (Stellenbosch University, SA). Cells were maintained in a monolayer at 37°C 
and in a 21% O2, 5% CO2, humidified air atmosphere of 95% and were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Invitrogen Gibco): Ham’s F12 nutrient mixture at a ratio of 1:1, 
supplemented with 10% fetal bovine serum (Invitrogen, Gibco) and 1% penicillin/streptomycin 
solution (Invitrogen, Gibco), 0.005 mg/ml insulin (Stelkor Pharmacy, Stellenbosch, SA), 50 nM 
hydrocortisone (Sigma Chemical Co., St Louis, MO, US)  and 20 mM HEPES (Sigma Chemical Co., 
St Louis, MO, US).  Cells were allowed to proliferate in T175 flasks (175 cm2 flasks). When cultures 
reached 80% confluency they were sub-cultured by washing the cell monolayer with warm (37°C) 
media (DMEM) followed by trypsinization using 0.25% Trypsin-ethylene-diaminetetra-acetic acid 
(trypsin-EDTA) (Invitrogen Gibco). Cells were gently agitated to ensure complete detachment from 
the flask followed by centrifugation at 1500 rpm for 3 minutes. Cell pellets were re-suspended in 
fresh warm growth medium and a hemocytometer was used to count the cells. Cells were 
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resuspended at a density of 16 x 106 in 300 µl of Hank’s Balanced Salt Solution (HBSS, Invitrogen 
Gibco). All harvested cells were used within 1 hour of preparation. 
2.2.3 Mammary tumor induction 
Mammary tumor induction was performed as previously described by Abbasalipourkabir et al. 
(2010). Rats were anesthetized by inhalation of 3% Isoflorane® (USP, Abbott Laboratories, USA) 
coupled with an oxygen regulator. Animals were orientated in a supine position. The injection site 
was cleaned and sterilized with ethanol. The cell suspension was aspirated using 1-cc (1-ml) TB 
syringes without needles to minimize cell lysis.  A 26 gauge needle was then attached to the TB 
syringe and the cell suspension was subcutaneously inoculated into the mammary fat pad (right 
flank) of the animal. The needle was inserted through the skin approximately 2 mm anterior and 3 
mm lateral to the mammary and then inserted 5 mm into the mammary fat pad. The 300 μl cell 
suspension was injected slowly over five minutes.  
 
All animals were monitored daily for mammary tumor development. Tumors were palpable 3 days 
post-inoculation. Tumor diameters and animal weight were measured daily. The tumor mass was 
measured horizontally and vertically, parallel to the ventricular surface of the rats, using a digital 
caliper.  The volume of the tumor (V) was calculated according to Carlsson et al. (1983): V=(ab2)/2, 
where ‘a’ and ‘b’ is the longest and shortest diameter of the tumor, respectively. 
 
2.2.4 Doxorubicin treatment 
DXR (Sigma Chemical Co., St Louis, MO, US) was prepared by dissolving the compound in Hank’s 
Balanced Salt Solution (HBSS, Invitrogen Gibco). The amount of DXR to be injected was calculated 
according to the average body weight of animals.  A 22 gauge needle was used to administer 200 
µl of DXR solution through the intraperitoneal injection. The DXR and DXR+MLT groups received a 
total of three intraperitoneal injections of DXR (4 mg/ kg) at three day intervals with an accumulative 
dose of 12 mg/kg.  
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2.2.5 Melatonin treatment 
Melatonin (MLT) (Sigma, St. Louis, MO) was orally administered to Sprague Dawley via the drinking 
water at a dose of 6 mg/rat/day. The amount of drinking water consumed by the group of animals 
per cage was monitored and recorded for one week prior to the commencement of the study and 
thus the average volume of drinking water consumed per animal was calculated. On the basis of the 
pre-determined water consumption of 50 ml/rat/day, MLT was dissolved in 700 ml of drinking water 
at a final concentration of 30 µg/ml. The water bottles were covered with aluminum foil as melatonin 
is a light sensitive compound; clean bottles with fresh solutions were prepared daily. The dosage of 
6 mg/kg/day was regularly adjusted according to the body weight gain of the animals which was 
measured daily. Animals drank water and MLT (6 mg/kg/day) ad libitum. Since a small volume of 
MLT was used in this study, it was completely dissolvable in the large volume of drinking water 
provided, therefore it was not necessary to dissolve the MLT in ethanol prior to adding it to the 
drinking water. 
2.2.6 Isolated rat heart perfusions 
Hearts were perfused with a modified Krebs-Henseleit bicarbonate buffer (KHB) containing: sodium 
chloride (NaCl, 119 mM), sodium bicarbonate (NaHCO3, 24.9 mM), potassium chloride (KCl, 4.7 
mM), potassium monophosphate (KH2PO4, 1.2 mM), magnesium sulphate heptahydrate 
(MgSO4.7H2O, 0.59 mM), sodium sulphate (Na2SO4, 0.59 mM), calcium chloride dihydrate 
(CaCl2.2H2O, 1.25 mM) and glucose (10 mM). The KHB was kept at a constant of pH 7.4; 
oxygenation was achieved by gassing the perfusate with 95% O2 and 5% CO2 at 37°C.  
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2.2.6.1 Perfusion technique of isolated perfused rat heart 
Upon termination of the experimental protocol, rats were anaesthetized using sodium pentobarbitone 
(160 mg/kg) via intraperitoneal injection, and body weights were recorded. The hearts were rapidly 
excised and immediately arrested in ice-cold (4°C) Krebs-Henseleit bicarbonate buffer (KHB). 
Thereafter, hearts were mounted onto the aortic cannula via the aorta. After cannulation, stabilization 
of the heart was achieved by perfusing the hearts retrogradely (Langendorff mode), in a non-
recirculating manner at constant hydrostatic pressure (100 cm H2O) for 15 minutes.  During this time, 
the left atrium was cannulated via the pulmonary vein to allow atrial perfusion (atrial pressure 15 cm 
H2O). The left ventricle ejected against a hydrostatic pressure of 100 cm H2O. After 15 minutes of 
retrograde perfusion, the perfusion mode was switched to the working heart mode maintaining a 
preload of 15 cm H2O and an afterload of 100 cm H2O for 15 minutes. Myocardial temperature was 
maintained at 37°C and thermostatically controlled as well as continuously monitored by inserting a 
temperature probe into the pulmonary artery. At the end of the perfusion protocol, hearts were 
weighed and immediately freeze-clamped with Wollenberger tongs and submerged in liquid nitrogen. 
The heart tissue samples were stored at - 80°C until further use. 
2.2.6.2 Determination of cardiac function 
Coronary (Qe) and aortic (Qa) flow rates in ml/minute were measured manually. The aortic pressure 
(mmHg) and heart rate was recorded using a Viggo-Spectramed pressure transducer which was 
connected to a computer and attached to the side-arm of the aortic cannula. The peak systolic 
pressure (PSP) was obtained from the recordings. The following parameters were calculated to 
assess cardiac function: Cardiac output (CO) (ml/min) = (Aortic flow rate + Coronary flow rate), 
Stroke volume (SV) (ml/min) = (Cardiac output/Heart rate) and, Total Work performance (TW, 
mWatts) which is the mean external power produced by the left ventricle was calculated using a 
formula previously described by Kannengieser et al. (1979): 0.002222 (PAO -11.25) (CO) where 
PAO = aortic pressure, CO = cardiac output. 
  
Stellenbosch University  https://scholar.sun.ac.za
43 | P a g e  
 
2.2.7 Immunoblot Analysis 
2.2.7.1 Tissue Protein Extraction 
Heart tissues were retrieved from the - 80 °C freezer and immediately placed in liquid nitrogen. Small 
pieces of tissue were cut, weighed, ground to powder by gently tapping it with a pre-cooled pestle 
and, homogenized in 1 ml of cold Radioimmunoprecipitation assay (RIPA) buffer using a Polytron 
PT10 homogenizer. The RIPA buffer, pH 7.4, contained: Tris-HCL (2.5 mM), EDTA (1 mM), Sodium 
Fluoride (NaF, 50 mM), Sodium orthovanadate (Na3VO4, 1 mM), soybean trypsin inhibitor (SBTI, 4 
μg/ml), phenyl-methyl-sulphonyl fluoride (PMSF, 0.1 mM), Leupeptin (10 mg/ml), Benzamidine (1 
mM), Nonidet-P40 (NP-40, 1%) and Sodium Deoxycholate (NADC, 0.5%). Samples were then 
centrifuged at 12 000 rpm for 15 minutes at -4°C, the supernatant was transferred into pre-chilled 
microtubes and stored at -80°C until further use.  
2.2.7.2 Mitochondrial Isolation from Tissue and Protein Extraction  
Mitochondrial isolation was performed using the Mitochondrial Isolation Kit for Tissue (Abcam, 
ab110168) according to the manufacturer’s instructions. Frozen heart tissue was weighed (0.4 g as 
recommended to yield 1- 2 mg of isolated mitochondria). The sample tissue was washed twice with 
1.5 ml of Wash Buffer (Abcam, ab110168). The tissue was minced and homogenized using a pre-
chilled Dounce Homogenizer (40 dounce strokes as recommended) in 2 ml of Isolation Buffer 
(Abcam, ab110168). The homogenate was transferred to 2 ml microtubes, filled to a volume of 2 ml 
with Isolation buffer and centrifuged at 2000 rpm for 10 minutes at 4°C. The supernatant was 
separated into equal volumes using two microtubes and filled to a volume of 2 ml with Isolation 
buffer. Both samples of the supernatant were centrifuged at 8000 rpm for 15 minutes at 4°C. Both 
pellets were resuspended in 1 ml of isolation buffer supplemented with 10 μl of protease inhibitor 
cocktail (ABCAM, ab65621) and centrifuged at 8000 rpm for 15 minutes at 4°C and this step was 
repeated twice. The pellets were then combined and resuspended in 500 μl of Isolation Buffer and 
supplemented with 0.5 μl of protease inhibitor cocktail. The samples were then stored at -80°C until 
use.  
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2.2.7.3 Protein Determination, Sample Preparation, SDS-PAGE, Electrotransfer and 
Immuno-detection 
The methodology was similar as previously described in sections 2.1.10.3 - 2.1.10.5. Protein 
expression was normalized to the corresponding total protein per sample.  
 
2.2.8 Statistical Analyses 
Values are expressed as mean ± standard error of the mean (SEM). Analysis of data was 
conducted using GraphPad Prism, version 5.0 (GraphPad Inc.). One-way Analysis of Variance 
(ANOVA) with Bonferroni’s Multiple Comparison as a post-hoc test was used to assess the 
statistical significance between treatment groups. Two-way repeated measures ANOVA with 
Fisher's LSD as a post-hoc test was used to assess the statistical significance between treatment 
groups and day on tumor volume or animal weight. Values of p<0.05 were considered significant. 
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Chapter 3 
 
Results 
3.1 Pilot study 
A dose and time response study was initially conducted to determine clinically relevant doxorubicin 
(DXR) and melatonin (MLT) concentrations and treatment durations for the main study. 
3.1.1 The effect of various Doxorubicin (DXR) concentrations on cell viability 
In order to determine a treatment concentration of DXR, H9c2 cardiac myoblasts were incubated 
with 1, 2, 3, 4, and 5 µM of DXR for 24 hours and cell viability was assessed using the MTT assay. 
Cells treated with DXR at a concentration of 3 µM and 5 µM for 24 hours significantly decreased cell 
viability when compared to the CTRL (39.67 ± 7.688% vs 100%, p < 0.001; 38.67 ± 8.413% vs 100%, 
p < 0.001, respectively) (Figure 3.1.1). The lower concentration of 3 µM of DXR was chosen for this 
study as it is within the clinically relevant range for DXR treatment. 
 
 
 
 
 
 
 
Figure 3.1.1: The effect of various DXR concentrations on the cell viability of H9c2 cardiac myoblasts. 
Cells were treated with increasing concentrations of DXR for 24 hours. Cell viability was assessed using the 
MTT Assay. Values are expressed as a percentage of the control and presented as means ± SEM (n=3), *p < 
0.001 vs CTRL. Abbreviations- CTRL: control; DXR: doxorubicin. 
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3.1.2 The effect of various melatonin (MLT) concentrations on cell viability 
In order to determine a treatment concentration of MLT, H9c2 cardiac myoblasts were incubated 
with 10, 20, and 50 µM of MLT for 24 hours and cell viability was assessed using the MTT assay. 
Cells treated with MLT at a concentration of 50 µM for 24 hours significantly decreased cell viability 
when compared to the CTRL (68.33 ± 6.741% vs 100%, p < 0.05). A concentration of 10 µM of MLT 
was chosen for this study, as there was no significant change in cell viability in comparison to the 
CTRL (Figure 3.1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.2: The effect of various MLT concentrations on the cell viability of H9c2 cardiac myoblasts. 
Cells were treated with increasing concentrations of MLT for 24 hours. Cell viability was assessed using the 
MTT Assay. Values are expressed as a percentage of the control and presented as means ± SEM (n=3), *p < 
0.05 vs CTRL. Abbreviations- CTRL: control; VEH CTRL: vehicle control; MLT: melatonin. 
 
 
3.1.3 The effect of MLT pre-treatment on cell viability and doxorubicin-induced cell 
death 
In order to determine a treatment duration for MLT, H9c2 cardiac myoblasts were pre-treated with 
10 µM of MLT for 1 hour and 24 hours followed by incubation with DXR (3 µM) for 24 hours. Cell 
viability was assessed using the MTT assay. No significant changes in cell viability were 
demonstrated when cells were pre-treated with MLT for 1 hour followed by DXR treatment in 
comparison to the DXR treated group only. However, the viability of H9c2 cells pre-treated with MLT 
for 24 hours followed by DXR treatment significantly increased in comparison to the DXR treated 
group (76.33 ± 6.642% vs 35.67 ± 6.566, p < 0.001) (Figure 3.1.3).  
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Figure 3.1.3: The effect of MLT pre-treatment on the cell viability and DXR-induced cell death. Cells 
were treated with 10 µM MLT for 1 hour and 24 hours followed by incubation with 3 µM DXR for 24 hours. Cell 
viability was assessed using the MTT Assay. Values are expressed as a percentage of the control and 
presented as means ± SEM (n=3), #p < 0.001 vs DXR. Abbreviations- CTRL: control; VEH CTRL: vehicle 
control; DXR: doxorubicin; MLT: melatonin; hr: hour. 
 
 
Based on the results obtained in the pilot study, pre-treatment with MLT at a concentration of 10 µM 
for 24 hours was chosen for future in vitro experiments as it induced a protective effect against DXR-
induced cell death. Therefore, the following five treatment groups were used in this study: (i) control 
(CTRL); (ii) vehicle control (VEH CTRL, 0.02% EtOH); (iii) doxorubicin (DXR) at 3 µM for 24 hours; 
(iv) melatonin (MLT) at 10 µM for 24 hours and (v) pre-treatment with melatonin followed by 
doxorubicin exposure (DXR+MLT). 
 
3.2 The effect of MLT on cell viability and apoptosis during DXR-induced 
cardiotoxicity 
3.2.1 Trypan blue assay  
To further confirm the results of the MTT assay, cell viability was additionally assessed using the 
trypan blue assay. Cell viability significantly decreased in the DXR treated group in comparison to 
the CTRL (36.67 ± 4.806% vs 100%, p < 0.001). However, pre-treatment with MLT for 24 hours 
significantly increased the amount of viable cells in comparison to DXR treated group (75.67 ± 
7.535% vs 36.67 ± 4.806%) (Figure 3.2.1).  
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Figure 3.2.1: The effect of MLT on the cell viability during DXR-induced cardiotoxicity. Cells were treated 
with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours. Cell viability was assessed 
using the Trypan blue assay. Values are expressed as a percentage of the control and presented as means ± 
SEM (n=3), *p < 0.001 vs CTRL, #p < 0.01 vs DXR. Abbreviations- CTRL: control; VEH CTRL: vehicle control; 
DXR: doxorubicin; MLT: melatonin. 
 
3.2.2 Caspase 3/7 activity assessment  
H9c2 cells displayed a significant increase in caspase 3/7 activity in response to DXR treatment 
when compared to the CTRL (2.393 ± 0.093 fold vs 1.000 ± 0.000 fold, p < 0.001) (Figure 3.2.2). 
However, a significant decrease in caspase 3/7 activity was detected when cells were pre-treated 
with MLT for 24 hours followed by treatment with DXR for 24 hours when compared to the DXR 
treated group only (1.710 ± 0.076 fold vs ± 2.393 ± 0.093 fold, p < 0.001) (Figure 3.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2: The effect of MLT on the caspase 3/7 activity during DXR-induced cell death. Cells were 
treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours. Cell viability was 
assessed using the Caspase-Glo® 3/7 Assay. Caspase 3/7 activity was taken to be proportionate to the 
produced luminescence intensity per sample. Results represent the fold change in luminescence and are 
presented as means ± SEM (n=3), *p < 0.001 vs CTRL, **p < 0.001 vs CTRL, #p < 0.001 vs DXR. 
Abbreviations- CTRL: control; VEH CTRL: vehicle control; DXR: doxorubicin; MLT: melatonin; AU: arbitrary 
units. 
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The VEH CTRL (0.02% EtOH) shows a significant increase in caspase activity in comparison to the 
CTRL (1.647 ± 0.067 fold vs 1.000 ± 0.000 fold, p < 0.001), however this discrepancy may be 
attributed to the reaction of ethanol with the reagents supplied in the Caspase-Glo Promega Kit as 
no change in cell viability was demonstrated when the MTT assay and trypan blue cell viability 
assays were conducted.  
 
3.2.3 Immunoblot analysis of cleaved caspase-3 and cleaved PARP protein levels  
To further assess programmed cell death and confirm that the vehicle control (0.02% EtOH) is not 
inducing cell death in our model, immunoblot analysis for apoptotic proteins cleaved caspase-3 and 
cleaved PARP were performed. Caspase-3 cleavage significantly increased in response to DXR 
treatment when compared to the CTRL (237.7 ± 16.56% vs 100%, p < 0.001) (Figure 3.2.3 A). Cells 
pre-treated with MLT were able to mitigate this effect and significantly decreased caspase-3 
cleavage in comparison to the DXR treated group (126.6 ± 10.52% vs 237.7 ± 16.56%, p < 0.001) 
(Figure 3.2.3 A).  
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Figure 3.2.3: The effect of MLT on cleaved caspase-3 and PARP cleavage during DXR-induced cell 
death. Cells were treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours. 
Apoptotic cell death was assessed using immunoblot analysis. Bar graphs show: A. Cleaved caspase-3 and 
B. Cleaved-PARP protein levels (normalized to β-actin vs control). Values are expressed as a percentage of 
the control and presented as means ± SEM (n=3), A: *p < 0.001 vs CTRL, #p < 0.001 vs DXR. B: *p < 0.001 
vs CTRL, #p < 0.05 vs DXR. Abbreviations- CTRL: control; VEH CTRL: vehicle control; DXR: doxorubicin; 
MLT: melatonin. 
  
 
 
Similar results were observed in response to PARP cleavage.  The DXR treated group significantly 
increased PARP cleavage in comparison to the CTRL (264.9 ± 11.26% vs 100%, p < 0.001) and 
pre-treatment with MLT significantly decreased PARP cleavage in comparison to the DXR group 
(162.8 ± 35.38% vs 264.9 ± 11.26%, p < 0.001) (Figure 3.2.3 B). Since the VEH CTRL (0.02% EtOH) 
showed no significant changes in caspase-3 and PARP cleavage in comparison to the CTRL, the 
VEH CTRL was not included in further analyses as we were confident that it had no effect.  
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3.3 The effect of MLT on autophagy during DXR-induced cardiotoxicity 
 
3.3.1 Immunoblot analysis of autophagy proteins LC3 II and SQSTM1/p62  
To assess autophagic flux, four additional treatment groups were included in this analysis. H9c2 
cells were treated as previously described and at the end of each treatment, cells were treated 
additionally with an autophagic inhibitor bafilomycin A1 (BAF) at a concentration of 10 nM for 4 hours. 
Immunoblot analysis was conducted to assess the protein levels of LC3 II and p62.  
 
Figure 3.3.1: The effect of MLT on autophagy during DXR-induced cardiotoxicity. Cells were treated with 
10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours and thereafter treated with 10 nM 
BAF for 4 hours. Autophagic flux was assessed using immunoblot analysis. Bar graphs show: A. LC3 II and 
B. SQSTM1/p62 protein levels (normalized to β-actin vs control). Values are expressed as a percentage of 
the control and presented as means ± SEM (n=4), A: *p < 0.05 vs CTRL, **p < 0.01 vs DXR, #p < 0.05 vs MLT. 
B: *p < 0.05 vs DXR+MLT. Abbreviations- CTRL: control; DXR: doxorubicin; MLT: melatonin; BAF: 
Bafilomycin A1. 
 
There was a significant increase in LC3 II levels when cells were treated with BAF in comparison to 
the CTRL (149 ± 7.90% vs 100%, p < 0.05). Cells treated with DXR+BAF significantly increased LC3 
II levels in comparison to the DXR treated group (120.8 ± 11.43% vs 56.16 ± 11.92%, p < 0.01).  
Similarly, MLT+BAF increased LC3 II levels significantly in comparison to the MLT group (131 ± 
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6.137% vs 73.02 ± 12.05%, p < 0.05) (Figure 3.3.1 A). Interestingly, no significant changes in LC3 
II levels occurred with the DXR+MLT treated group in comparison to the DXR+MLT+BAF group. 
Furthermore, no significant changes in p62 levels occurred when cells were treated with BAF in 
comparison to the CTRL. However, cells treated with DXR+MLT+BAF significantly decreased p62 
levels in comparison to the DXR+MLT treated group (45.16 ± 6.57% vs 92.29 ± 10.49%, p < 0.05) 
(Figure 3.3.1 B). 
 
3.3.2 Immunoblot assessment of Pink1 and PARKIN protein levels 
Pink1 and PARKIN proteins are associated with mitophagy. To assess Pink1 and PARKIN protein 
levels, cells were treated with MLT at 10 µM for 24 hours followed by incubation with DXR at 3 µM 
for 24 hours and the mitochondria were isolated at the end of treatment from each group. Pink1 
which is an indicator of mitochondrial damage, significantly increased in response to DXR treatment 
in comparison to the CTRL (274.9 ± 36.58% vs 100%, p < 0.01) (Figure 3.3.2 A).  
Figure 3.3.2: The effect of MLT on Pink1 and PARKIN during DXR-induced cardiotoxicity. Cells were 
treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours. Mitochondria were 
isolated from treated cells and Pink1 and PARKIN were assessed using immunoblot analyses. Bar graphs 
show: A. Pink1 and B. PARKIN protein levels (normalized to TOM20 vs control). Values are expressed as a 
percentage of the control and presented as means ± SEM (n=3), A: *p < 0.01 vs CTRL, #p < 0.01 vs DXR. B: 
*p < 0.001 vs DXR. Abbreviations- CTRL: control; DXR: doxorubicin; MLT: melatonin. 
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Pink1 levels were significantly decreased in the MLT treated group in comparison to the DXR group 
(103 ± 11.26% vs 274.9 ± 36.58%, p < 0.01) (Figure 3.3.2 A). However, no significant changes in 
protein levels of Pink1 occurred between DXR+MLT and the DXR group.  Furthermore, DXR+MLT 
treatment significantly increased PARKIN protein levels in comparison to the DXR treated group only 
(320.7 ± 31.78% vs 72.06 ± 21.18%, p < 0.001) (Figure 3.3.2 B). 
 
3.4 The effect of MLT on ROS and mitochondrial ROS generation during DXR-
induced cardiotoxicity 
 
3.4.1 Flow cytometry analysis of ROS generation with H2DCFDA and MitoSox Red 
staining 
H9c2 cells were treated as previously described and stained with H2DCFDA and MitoSox Red to 
quantify ROS and mitochondrial ROS generation, respectively. The mean fluorescent intensity was 
measured using flow cytometry analysis. 
 
Figure 3.4.1: The effect of MLT on ROS and mitochondrial ROS generation during DXR-induced 
cardiotoxicity. Cells were treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 
hours. Cells were then stained with H2DCFDA and MitoSox Red and analyzed using flow cytometry to measure 
ROS and mitochondrial ROS, respectively. Bar graphs show: A. ROS generation and B. Mitochondrial ROS 
Values are expressed as a percentage of the control and presented as means ± SEM (n=4), A: *p < 0.05 vs 
DXR, B: *p < 0.001 vs CTRL, #p < 0.001 vs DXR. Abbreviations- CTRL: control; DXR: doxorubicin; MLT: 
melatonin. 
 
ROS generation significantly decreased when cells were pre-treated with MLT for 24 hours in 
comparison to the DXR treated group only (67.27 ± 14.70% vs 117.3 ± 11.45%, p < 0.05) (Figure 
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3.4.1 A). However, the increase in ROS generation induced by DXR treatment was not significant in 
comparison to the CTRL (Figure 3.4.1 A).  
DXR treatment significantly increased mitochondrial ROS production in comparison to the CTRL 
(681.8 ± 42.58% vs 100%, p < 0.001) (Figure 3.4.1 B).  Pre-treatment with MLT significantly 
decreased mitochondrial ROS generation induced by the DXR (335.0 ± 40.08% vs 681.8 ± 42.58%, 
p < 0.001) (Figure 3.4.1 B). 
 
3.5 The effect of MLT on mitochondrial membrane potential during DXR-induced 
cardiotoxicity 
 
3.5.1 Flow cytometry analysis of mitochondrial membrane potential with JC-1 
staining 
H9c2 cells were treated as previously described and stained with JC-1 to assess mitochondrial 
membrane potential.  JC-1 is a ratio metric dye and therefore the PE/FITC (red/green) mean 
fluorescent intensity was measured using flow cytometry analysis 
Treatment with 3 µM DXR for 24 hours significantly decreased mitochondrial membrane potential in 
comparison to the CTRL (63.80 ± 10.97% vs 100%, p < 0.05) (Figure 3.5.1). Interestingly, treatment 
with MLT significantly increased mitochondrial membrane potential in comparison to the CTRL 
(143.8 ± 8.866% vs 100%, p < 0.01). In addition, cells pre-treated with MLT significantly increased 
mitochondrial membrane potential when compared to the DXR group (105.3 ± 5.105% vs 63.80 ± 
10.97%, p < 0.05) (Figure 3.5.1). 
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Figure 3.5.1: The effect of MLT on mitochondrial membrane potential during DXR-induced 
cardiotoxicity. Cells were treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 
hours. Cells were then stained with JC-1 and analyzed using flow cytometry to measure the mean fluorescent 
intensity (PE/FITC). Values are expressed as a percentage of the control and presented as means ± SEM 
(n=4), *p < 0.05 vs CTRL, **p < 0.01 vs CTRL, #p < 0.05 vs DXR. Abbreviations- CTRL: control; DXR: 
doxorubicin; MLT: melatonin. 
 
 
3.6 The effect of MLT on mitochondrial dynamics during DXR-induced cardiotoxicity 
 
3.6.1 Mitochondrial Morphometric Network Assessment 
 In order to assess the mitochondrial network, H9c2 cells were treated and stained with Hoechst and 
TMRE. Live cell imaging was performed. A morphometric assessment of the mitochondrial network 
was conducted on the processed images as previously described by Mortiboys et al. (2008), using 
ImageJ (version 1.42) software (see section 2.1.8). 
 A high degree of mitochondrial fission (round-shaped mitochondria) following DXR treatment 
occurred in comparison to the CTRL group which maintained a healthy fused mitochondrial network 
(long, elongated mitochondria) (Figure 3.6.1.1). Pre-treatment with melatonin followed by DXR 
treatment decreased the degree of mitochondrial fission in comparison to the DXR treated group 
(Figure 3.6.1.1).   
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Figure 3.6.1.1: Fluorescence microscopy images of H9c2 cells which were treated and stained with 
Hoechst (blue) and TMRE (red) to visualize the cell nucleus and mitochondrial network, respectively. 
Abbreviations- CTRL: control; DXR: doxorubicin; MLT: melatonin. 
 
Cells treated with DXR for 24 hours significantly deceased the mitochondrial major/minor aspect 
ratio in comparison to the CTRL (1.162 ± 0.1279 vs 3.834 ± 0.2689, p < 0.001) (Figure 3.6.1.2 A). 
However, pre-treatment with MLT significantly increased the major/minor aspect ratio of 
mitochondria when compared to the DXR group (3.174 ± 0.5138 vs 1.162 ± 0.1279, p < 0.05) (Figure 
3.6.1.2 A). Similarly, treatment with DXR significantly decreased the degree of mitochondrial 
branching in comparison to the CTRL (1.867 ± 0.4055 vs 4.190 ± 0.3934, p < 0.05) (Figures 3.6.1.1 
and 3.6.1.2 B). Pre-treatment with MLT significantly increased the degree of branching in 
comparison to the DXR group (4.317 ± 0.5800 vs 1.867 ± 0.4055, p < 0.05) (Figure 3.6.1.2 B). 
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Figure 3.6.1.2: The effect of MLT on the mitochondrial network during DXR-induced cardiotoxicity. A 
morphological and network assessment of the mitochondria was conducted on the processed images. Bar 
graphs show: A. Major/minor aspect ratio and B. Degree of branching. Values are presented as means ± SEM 
(n=4), A: *p < 0.001 vs CTRL, #p < 0.05 vs DXR, B: *p < 0.05 vs CTRL, #p < 0.05 vs DXR. Abbreviations- 
CTRL: control; DXR: doxorubicin; MLT: melatonin; AU: arbitrary units. 
 
 
 
3.6.2 Immunoblot analysis of mitochondrial fission and fusion proteins 
To confirm the results of the mitochondrial network assessment, immunoblot analysis for key 
mitochondrial fusion proteins (Mfn1, Mfn2 and OPA1) and fission proteins (Drp1 and hFis1) were 
conducted.  
DXR treatment significantly decreased the protein level of Mfn1 in comparison to the CTRL (54.78 
± 11.75% vs 100%, p < 0.001) (Figure 3.6.2.1 A). Pre-treatment with MLT followed by DXR treatment 
resulted in a significant increase in Mfn1 protein level (85.39 ± 13.15% vs 54.78 ± 11.75%, p < 0.01) 
(Figure 3.6.2.1 A). Similarly, Mfn2 protein level significantly decreased in response to DXR treated 
cells in comparison to the CTRL (42.68 ± 9.992% vs 100%, p < 0.001) (Figure 3.6.2.1 B), whereas 
MLT pre-treatment significant increased the protein level of Mfn2 in comparison to the DXR group 
(86.61 ± 6.278% vs 42.68 ± 9.992%, p < 0.01) (Figure 3.6.2.1 B). Interestingly, no significant changes 
in the Long-form of OPA1 (L-OPA1) expression was observed among the all treatment groups 
(Figure 3.6.2.2). L-OPA1 was quantified as it the pre-dominant isoform of OPA1. 
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Figure 3.6.2.1: The effect of MLT on mitochondrial fusion proteins Mfn1 and Mfn2 during DXR-induced 
cardiotoxicity. Cells were treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 
hours. Mitochondria were isolated from treated cells and fusion protein levels were assessed using immunoblot 
analysis. Bar graphs show: A. Mfn1 and B. Mfn2 protein levels (normalized to TOM20 vs control). Values are 
expressed as a percentage of the control and presented as means ± SEM (n=4), A: *p < 0.001 vs CTRL, #p < 
0.01 vs DXR. B: *p < 0.001 vs CTRL, #p < 0.01 vs DXR. Abbreviations- CTRL: control; DXR: doxorubicin; 
MLT: melatonin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2.2: The effect of MLT on mitochondrial fusion protein OPA1 during DXR-induced 
cardiotoxicity. Cells were treated with MLT at 10 µM for 24 hours followed by incubation with DXR at 3 µM 
for 24 hours. Mitochondria were isolated from treated cells and fusion protein levels of OPA1 was assessed 
using immunoblot analysis. Bar graph illustrates L-OPA1 protein levels (normalized to TOM20 vs control). 
Values are expressed as a percentage of the control and presented as means ± SEM (n=4), no significant 
changes occurred. Abbreviations- CTRL: control; DXR: doxorubicin; MLT: melatonin. 
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Mitochondrial fission protein Drp1 levels significantly increased in response to DXR treatment in 
comparison to the CTRL group (330.7 ± 26.45% vs 100%, p < 0.001) (Figure 3.6.2.3 A). No 
significant changes in Drp1 protein levels occurred with the MLT treated group in comparison to the 
CTRL. However, Drp1 protein levels significantly decreased when cells were pre-treated with MLT 
in comparison to the DXR treated group (87.13 ± 20.45% vs 330.7 ± 26.45%, p < 0.001) (Figure 
3.6.2.3 A).  
 
A similar trend was observed with hFis1 protein expression levels. hFis1 protein levels significantly 
increased in the DXR treated group in comparison to the CTRL (438.1 ± 17.31% vs 100%, p < 0.001) 
and a significant decrease in hFis1 protein levels occurred when cells were pre-treated with MLT 
(306.9 ± 32.79% vs 438.1 ± 17.31%, p < 0.001) (Figure 3.6.2.3 B). 
 
 
 
 
Figure 3.6.2.3: The effect of MLT on mitochondrial fission proteins Drp1 and hFis1 during DXR-induced 
cardiotoxicity. Cells were treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 
hours. Mitochondria were isolated from treated cells and fission protein levels were assessed using 
immunoblot analysis. Bar graphs show: A. Drp1 and B. hFis1 protein levels (normalized to TOM20 vs control). 
Values are expressed as a percentage of the control and presented as means ± SEM (n=4), A: *p < 0.001 vs 
CTRL, #p < 0.001 vs DXR. B: *p < 0.001 vs CTRL, #p < 0.01 vs DXR. Abbreviations- CTRL: control; DXR: 
doxorubicin; MLT: melatonin. 
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3.7 The effect of MLT on mitochondrial bioenergetics and biogenesis during DXR-
induced cardiotoxicity 
 
3.7.1 Mitochondrial respiration 
Mitochondrial respiration was assessed using the Seahorse XFe 96 Extracellular Flux Analyzer. 
H9c2 cells were treated as previously described and the oxygen consumption rate (OCR) was 
measured in real time at the end of treatments. The basal respiration rate (BRR), ATP-linked 
respiration, electron transport system capacity (ETS) and Mitochondrial Spare Respiratory Capacity 
(MSRC) (see section 2.1.9.2) were measured. 
There were no significant changes in the basal oxygen consumption rate among the treated groups. 
Interestingly, no significant changes in ATP-linked respiration occurred as well. However, MLT pre-
treatment significantly increased the ETS capacity in comparison to DXR treated group (125.6 ± 
3.784% vs 99.06 ± 5.825%, p < 0.01) (Figure 3.7.1.1 C). A similar trend was observed as MLT pre-
treatment significantly increased MSRC in comparison to DXR treated group (155.2 ± 5.879% vs 
105.1 ± 13.02%, p < 0.05) (Figure 3.7.1.1 D). 
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Figure 3.7.1.1: The effect of MLT on mitochondrial respiration during DXR-induced cardiotoxicity. Cells 
were treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours. Oxygen 
consumption rate was measured using the Seahorse XFe 96 Extracellular Flux Analyzer. Bar graphs show: A. 
Basal Respiration Rate, B. ATP-linked respiration, C. Electron transport system capacity and D. Mitochondrial 
Spare Respiratory Capacity. Values are expressed as a percentage of the control and presented as means ± 
SEM (n=12 replicates/group), C: *p < 0.01 vs DXR, D: *p < 0.05 vs DXR. Abbreviations- CTRL: control; DXR: 
doxorubicin; MLT: melatonin. 
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3.7.2 ATP Analysis 
In addition to measuring mitochondrial respiration an ATP assay was used to quantify cellular ATP 
content after cells were treated. The ATP concentration significantly decreased in response to DXR 
treatment in comparison to the CTRL (42.91 ± 5.049 nM/µg of protein vs 67.75 ± 4.392 nM/µg of 
protein, p < 0.05) (Figure 3.7.2.1). Pre-treatment with MLT significantly increased ATP concentration 
in comparison to the DXR treated group (75.91 ± 6.355 nM/µg of protein vs 42.91 ± 5.049 nM/µg of 
protein , p < 0.01) (Figure 3.7.2.1). 
 
 
 
 
 
 
 
 
 
Figure 3.7.2.1: The effect of MLT on cellular ATP levels during DXR-induced cardiotoxicity. Cells were 
treated with MLT at 10 µM for 24 hours followed by incubation with DXR at 3 µM for 24 hours. Cellular ATP 
levels were quantified using an ATP assay. Values are normalized to the amount of protein present in each 
sample and presented as means ± SEM (n=4), *p < 0.05 vs CTRL, #p < 0.01 vs DXR. Abbreviations- CTRL: 
control; DXR: doxorubicin; MLT: melatonin. 
 
 
 
 
3.7.3 Immunoblot analysis of Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α) 
 
Immunoblot analysis was conducted to measure the protein expression levels of PGC-1α, a key 
regulator of mitochondrial biogenesis. DXR treatment significantly decreased PGC-1α protein levels 
in comparison to the CTRL (11.41 ± 4.167% vs 100%, p < 0.001) (Figure 3.7.3.1). No significant 
changes in PGC-1α protein levels occurred with the MLT treated group in comparison to the CTRL. 
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However, MLT pre-treatment significantly increased PGC-1α protein levels in comparison to the DXR 
treated group (90.67 ± 12.23 % vs 11.41 ± 4.167 %, p < 0.001) (Figure 3.7.3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.3.1: The effect of MLT on PGC-1α during DXR-induced cardiotoxicity. Cells were treated with 
10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours. Protein levels of PGC-1α was 
assessed using immunoblot analysis. Bar graph illustrates PGC-1α protein levels (normalized to β-actin vs 
control). Values are expressed as a percentage of the control and presented as means ± SEM (n=4), *p < 
0.001 vs CTRL, #p < 0.001 vs DXR. Abbreviations- CTRL: control; DXR: doxorubicin; MLT: melatonin. 
 
 
 
3.8 The effect of MLT on sirtuin activity during DXR-induced cardiotoxicity 
 
3.8.1 Immunoblot analysis of SIRT1 and SIRT3 
Immunoblot analysis was conducted to measure the protein levels of SIRT1 and SIRT3. DXR 
treatment significantly decreased SIRT1 protein levels in comparison to the CTRL (44.5 ± 4.505% 
vs 100%, p < 0.001) and a significant decrease also occurred with MLT treatment in comparison to 
the CTRL (42.03 ± 6.847% vs 100%, p < 0.001) (Figure 3.8.1.1 A). Interestingly, pre-treatment with 
MLT increased SIRT1 protein levels in comparison to the DXR treated group (87.84 ± 6.373% vs 
44.5 ± 4.505%, p < 0.001) (Figure 3.8.1.1 A). 
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Figure 3.8.1.1: The effect of MLT on sirtuin activity during DXR-induced cardiotoxicity. Cells were 
treated with 10 µM MLT for 24 hours followed by incubation with 3 µM DXR for 24 hours. Sirtuin activity was 
assessed using immunoblot analysis.  Bar graphs show: A. SIRT1 and B. SIRT3 protein levels (normalized to 
β-actin or TOM20 vs control). Values are expressed as a percentage of the control and presented as means 
± SEM (n=4), A: *p < 0.001 vs CTRL, **p < 0.001 vs CTRL, #p < 0.001 vs DXR. B: *p < 0.05 vs CTRL, #p < 
0.05 vs DXR. Abbreviations- CTRL: control; DXR: doxorubicin; MLT: melatonin. 
 
 
Furthermore, SIRT3 protein levels significantly decreased in response to DXR treatment in 
comparison to the CTRL (40.24 ± 9.404% vs 100%, p < 0.05) (Figure 3.8.1.1 B). However, MLT pre-
treatment significantly increased SIRT3 protein levels in comparison to the DXR group (103.0 ± 
7.605% vs 40.24 ± 9.404%, p < 0.05) (Figure 3.8.1.1 B). 
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3.9 In vivo Study 
 
3.9.1 The effect of daily MLT administration on rat body weight during DXR- induced 
cardiotoxicity 
 
Female Sprague Dawley rats aged between 16-18 weeks were divided into six groups and treated 
as previously described (section 2.2 study design). A significant decrease in body weight was 
observed in DXR-treated rats in comparison to the V CTRL on day 10 (228.23 ± 6.75 g vs 263.43 ± 
1.25 g, p < 0.01). By day 14, the body weight of DXR-treated rats were significantly reduced in 
comparison to: T CTRL (222.22 ± 6.47 g vs 277.61 ± 7.90 g, p < 0.0001), the V CTRL (222.22 ± 6.47 
g vs 266.66 ± 7.68 g, p < 0.01), MLT-treated rats (222.22 ± 6.47 g vs 271.15 ± 8.98 g, p < 0.0001), 
and DXR+MLT-treated rats (222.22 ± 6.47 g vs 284.07 ± 6.53 g, p < 0.0001). 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.1: The effect of daily MLT administration on rat body weight during DXR-induced 
cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. The 
animal weights were recorded daily. CTRL (n=8); T CTRL (n=10); V CTRL (n=8); DXR (n=10); MLT (n=10); 
DXR+MLT (n=10). Abbreviations- CTRL: control; T CTRL: tumor control; V CTRL: vehicle control; DXR: 
doxorubicin; MLT: melatonin. 
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3.9.2 The effect of daily MLT administration on tumor growth during DXR-induced 
cardiotoxicity 
Animals were inoculated with LA7 rat tumor cells and treated as previously described (section 2.2.3). 
Tumors were palpable 3 days post-inoculation. Tumor volumes based on digital caliper 
measurements were calculated using the formula: V=(ab2)/2. Tumor volumes were significantly 
reduced in DXR+MLT-treated rats on day 8 in comparison to the DXR-treated rats (1668.10 ± 9.34 
mm3 vs 7332.74 ± 2038.04 mm3 , p < 0.05). By day 10, tumors were significantly reduced in DXR-
treated rats in comparison to the V CTRL (3661.98 ± 1421.97 mm3 vs 14386.11 ± 3220.527 mm3, p 
< 0.01), in MLT-treated rats in comparison to the T CTRL (1427.35 ± 774.89 mm3 vs 10506.66 ± 
1306.77 mm3, p < 0.001) and in DXR+MLT-treated rats in comparison to the T CTRL (150.27 ± 
150.27 mm3 vs 10506.66 ± 1306.77 mm3, p < 0.0001). 
 
 
 
 
 
 
 
 
Figure 3.9.2: The effect of daily MLT administration on rat tumor volume during DXR-induced 
cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. Tumors 
were measured daily and tumor volumes calculated (V=ab2/2). CTRL (n=8); T CTRL (n=10); V CTRL (n=8); 
DXR (n=10); MLT (n=10); DXR+MLT (n=10). Abbreviations- CTRL: control; T CTRL: tumor control; V CTRL: 
vehicle control; DXR: doxorubicin; MLT: melatonin. 
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3.9.3 The effect of daily MLT administration on rat heart weight during DXR-induced 
cardiotoxicity 
 
Upon termination of the experimental protocol, rats were anaesthetized and rat heart weights were 
recorded. Rat heart weights significantly decreased in DXR-treated rats in comparison to the V CTRL 
group (1.117 ± 0.02802 g vs 0.9635 ± 0.02807 g, p < 0.001). However, the heart weights of rats 
treated with DXR+MLT significantly increased in comparison to the DXR-treated rats (1.161 ± 
0.03454 g vs 0.9635 ± 0.02807 g, p < 0.001) (Figure 3.9.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9.3: The effect of daily MLT administration on rat heart weight during DXR-induced 
cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. The 
heart weights were recorded at the end of the study. Values are expressed as a percentage of the control and 
presented as means ± SEM (n=minimum of 8), A: *p < 0.01 vs V CTRL, #p < 0.001 vs DXR. Abbreviations- 
CTRL: control; T CTRL: tumor control; V CTRL: vehicle control; DXR: doxorubicin; MLT: melatonin. 
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3.9.4 The effect of daily MLT administration on cardiac function during DXR-induced 
cardiotoxicity 
 
Upon termination of the experimental protocol, rats were anaesthetized and hearts were rapidly 
excised to conduct isolated rat heart perfusions. The following parameters were assessed: cardiac 
output (ml/min), total work performance (mWatts), heart rate (beats/min), stroke volume (ml/beat) 
(section 2.2.6.2).  
 
Figure 3.9.4: The effect of daily MLT administration on cardiac function during DXR-induced 
cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. Isolated 
rat heart perfusions were conducted to assess cardiac function. Bar graphs indicate: A. Cardiac output, B. 
Total work performance, C. Stroke volume and D. Heart rate. Values are expressed as means ± SEM 
(n=minimum of 8), A: *p < 0.05 vs DXR, #p < 0.01 vs DXR. B: *p < 0.01 vs CTRL,**p < 0.05 vs DXR, #p < 
0.001 vs DXR. C: *p < 0.05 vs DXR. D: no significant changes. Abbreviations- CTRL: control; T CTRL: tumor 
control; V CTRL: vehicle control; DXR: doxorubicin; MLT: melatonin. 
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The cardiac output significantly increased in MLT-treated rats in comparison to the DXR-treated rats 
(55.15 ± 5.202 ml/min vs 39.25 ± 4.586 ml/min, p < 0.05). Cardiac output was significantly increased 
in DXR+MLT-treated rats in comparison to the DXR-treated rats (58.75 ± 1.633 ml/min vs 39.25 ± 
4.586 ml/min, p < 0.01) (Figure 3.9.4 A). 
 
A similar trend was observed when the total work performance was assessed. The total work 
performance of isolated rat hearts significantly decreased in DXR-treated rats in comparison to the 
CTRL (11.40 ± 0.5789 mWatts vs 7.661 ± 0.9279 mWatts, p < 0.01).  The total work performance of 
isolated rat hearts significantly increased in MLT-treated rats in comparison to the DXR-treated rats 
(10.40 ± 0.7339 mWatts vs 7.661 ± 0.9279 mWatts, p < 0.05). The total work performance 
significantly increased in DXR+MLT-treated rats in comparison to the DXR-treated rats (11.86 ± 
0.3423 mWatts vs 7.661 ± 0.9279 mWatts, p < 0.001) (Figure 3.9.4 B). 
 
Furthermore, the stroke volume of rats treated with DXR+MLT significantly increased in comparison 
to DXR-treated rats (10.40 ± 0.7339 mWatts vs 7.661 ± 0.9279 mWatts, p < 0.05) (Figure 3.9.4 C). 
However, no significant differences in heart rate occurred among the treated groups (Figure 3.9.4 
D).  
 
 
3.9.5 The effect of daily MLT administration on apoptosis during DXR-induced 
cardiotoxicity 
 
3.9.5.1 Immunoblot assessment of cleaved caspase-3 and cleaved PARP protein 
levels  
To provide further insight into programmed cell death, heart tissue from the various treated groups 
were analyzed using cleaved caspase-3 and cleaved-PARP as markers for apoptotic cell death. The 
presence of these markers in the treated groups were quantified using immunoblot analysis. Cleaved 
caspase-3 protein levels in the hearts of DXR-treated rats were significantly increased in comparison 
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to the V CTRL (383.1 ± 56.86% vs 149 ± 23.60%, p < 0.01). Cleaved caspase-3 significantly 
decreased in MLT-treated rats in comparison to DXR-treated rats (146.3 ± 36.36% vs 383.1 ± 
56.86%, p < 0.01). Furthermore, a significant decrease in cleaved caspase-3 protein levels occurred 
in DXR+MLT-treated rats in comparison to the DXR-treated group (152.8 ± 9.264% vs 383.1 ± 
56.86%, p < 0.01) (Figure 3.9.5.1 A). 
 
Figure 3.9.5.1: The effect of daily MLT administration on cleaved caspase-3 and PARP cleavage during 
DXR-induced cell death. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and 
DXR. Apoptotic cell death was assessed in rat hearts using immunoblot analysis. Bar graphs show: A. Cleaved 
caspase-3 and B. Cleaved-PARP protein levels (normalized to total protein vs control). Values are expressed 
as a percentage of the control and presented as means ± SEM (n=minimum of 3), A: *p < 0.01 vs V CTRL, 
**p < 0.01 vs DXR, #p < 0.01 vs DXR. B: *p < 0.01 vs V CTRL, **p < 0.001 vs DXR, #p < 0.001 vs DXR. 
Abbreviations- CTRL: control; T CTRL: tumor control; V CTRL: vehicle control; DXR: doxorubicin; MLT: 
melatonin. 
 
 
Similarly, PARP cleavage was significantly increased in DXR-treated rats in comparison to the V 
CTRL (328.3 ± 16.25% vs 185.0 ± 32.32%, p < 0.01). PARP cleavage in MLT-treated rats 
significantly decreased in comparison to the DXR-treated rats (135.2 ± 36.59% vs 328.3 ± 16.25%, 
p < 0.001). Additionally, a significant decrease in PARP cleavage occurred in DXR+MLT-treated rats 
in comparison to the DXR-treated group (75.83 ± 7.984% vs 328.3 ± 16.25%, p < 0.001) (Figure 
3.9.5.1 B). 
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3.9.6 The effect of daily MLT administration on autophagy during DXR-induced 
cardiotoxicity 
 
3.9.6.1 Immunoblot assessment of autophagy proteins LC3 II and SQSTM1/p62  
Heart tissue from the various treated groups were analyzed using LC3 II and SQSTM1/p62 as 
markers for autophagy. The presence of these markers in the treated groups were quantified using 
immunoblot analysis. A significant increase in LC3 II protein levels was observed in the heart tissue 
of DXR-treated rats in comparison to the V CTRL (151.9 ± 5.454% vs 100.9 ± 77.85%, p < 0.05). 
LC3 II protein levels were significantly increased in MLT-treated rats in comparison to the T CTRL 
(166.9 ± 7.842% vs 82.73 ± 6.395%, p < 0.001). Furthermore, LC3 II protein levels were significantly 
increased in DXR+MLT-treated rats in comparison to DXR-treated rats (205.0 ± 12.15% vs 151.9 ± 
5.454%, p < 0.01) (Figure 3.9.6.1 A). 
 
Figure 3.9.6.1: The effect of daily MLT administration on LC3 II and p62/SQSTM1 protein levels during 
DXR-induced cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and 
DXR. LC3 II and p62/SQSTM1 protein levels were assessed in rat hearts using immunoblot analysis. Bar 
graphs show: A. LC3 II and B. p62/SQSTM1 protein levels (normalized to total protein vs control). Values are 
expressed as a percentage of the control and presented as means ± SEM (n=minimum of 3), A: *p < 0.05 vs 
V CTRL, **p < 0.001 vs T CTRL, #p < 0.01 vs DXR. B: *p < 0.01 vs V CTRL, #p < 0.001 vs DXR. Abbreviations- 
CTRL: control; T CTRL: tumor control; V CTRL: vehicle control; DXR: doxorubicin; MLT: melatonin. 
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A significant increase in p62 protein levels was observed in the heart tissue of DXR-treated rats in 
comparison to the V CTRL (230.4 ± 17.39% vs 102.4 ± 28.74%, p < 0.01). A significant increase in 
LC3 II protein levels was also observed in DXR+MLT-treated rats in comparison to the DXR-treated 
group (378.5 ± 23.75% vs 230.4 ± 17.39%, p < 0.001) (Figure 3.6.9.1 B). 
 
3.9.6.2 Immunoblot analysis of Pink1 and PARKIN protein levels 
Pink1 and PARKIN proteins are associated with mitophagy. Mitochondria were isolated from rat 
heart tissue to assess the presence of these markers in the treated groups. Pink1 and PARKIN 
protein levels were quantified using immunoblot analysis. Pink1 protein levels were significantly 
increased in DXR-treated rats in comparison to the V CTRL (417.6 ± 24.12% vs 139.6 ± 36.79%, p 
< 0.001). However, a significant decrease in Pink1 protein levels occurred in DXR+MLT-treated rats 
in comparison to DXR-treated rats (103.3 ± 16.21% vs 417.6 ± 24.12%, p < 0.001) (Figure 3.9.6.2 
A). 
Similarly, PARKIN protein levels significantly increased in DXR-treated rats in comparison to the V 
CTRL (237.1 ± 32.22% vs 116.5 ± 27.27%, p < 0.05) (Figure 3.9.6.2 B). However, no significant 
changes in PARKIN protein levels occurred in DXR+MLT-treated rats in comparison to DXR-treated 
rats.  
 
Figure 3.9.6.2: The effect of daily MLT administration on Pink1 and PARKIN protein levels during DXR-
induced cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. 
Pink1 and PARKIN protein levels were assessed in rat hearts using immunoblot analysis. Bar graphs show: 
A. Pink1 and B. PARKIN protein levels (normalized to total protein vs control). Values are expressed as a 
percentage of the control and presented as means ± SEM (n=minimum of 3), A: *p < 0.001 vs V CTRL, #p < 
0.001 vs DXR. B: *p < 0.05 vs V CTRL. Abbreviations- CTRL: control; T CTRL: tumor control; V CTRL: vehicle 
control; DXR: doxorubicin; MLT: melatonin. 
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3.9.7 The effect of daily MLT administration on mitochondrial fusion and fission 
during DXR-induced cardiotoxicity 
 
3.9.7.1 Immunoblot analysis of mitochondrial fusion proteins 
Mitochondria were isolated from rat heart tissue and the protein levels of key mitochondrial fusion 
proteins (Mfn1, Mfn2 and OPA1) were assessed using immunoblot analysis. Mfn1 protein levels 
were significantly increased in DXR+MLT-treated rats in comparison to DXR-treated rats (109.8 ± 
12.49% vs 62.48 ± 7.752%, p < 0.05) (Figure 3.9.7.1 A ).  
 
 
 
 
 
 
 
 
 
Figure 3.9.7.1: The effect of daily MLT administration on Mfn1, Mfn2 and OPA1 protein levels during 
DXR-induced cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and 
DXR. Mfn1, Mfn2 and OPA1 protein levels were assessed in rat hearts using immunoblot analysis. Bar graphs 
show: A. Mfn1, B. Mfn2 and C. L-OPA1 protein levels (normalized to total protein vs control). Values are 
expressed as a percentage of the control and presented as means ± SEM (n=minimum of 3), A: *p < 0.05 vs 
DXR. B: *p < 0.05 vs V CTRL, #p < 0.001 vs DXR. C: no significant changes. Abbreviations- CTRL: control; T 
CTRL: tumor control; V CTRL: vehicle control; DXR: doxorubicin; MLT: melatonin. 
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Mfn2 protein levels were significantly decreased in DXR-treated rats in comparison to the V CTRL 
group (56.92 ± 3.393% vs 86.71 ± 12.09%, p < 0.05). Furthermore, a significant increase in Mfn2 
protein levels occurred in DXR+MLT-treated rats in comparison to DXR-treated rats (106.5 ± 4.142% 
vs 56.92 ± 3.393%, p < 0.001) (Figure 3.9.7.1 B). However, no significant changes in L-OPA1 levels 
were observed among the treated groups (Figure 3.9.7.1 C). 
3.9.7.2 Immunoblot analysis of mitochondrial fission proteins 
Protein levels of mitochondrial fission proteins (Drp1 and hFis1) were assessed using immunoblot 
analysis. Drp1 protein levels were significantly increased in DXR-treated rats in comparison to the 
CTRL (194.5 ± 15.53% vs 100%, p < 0.01). Drp1 protein levels were significantly decreased in 
DXR+MLT-treated rats in comparison to DXR-treated rats (74.13 ± 12.80% vs 194.5 ± 15.53%, p < 
0.001) (Figure 3.9.7.2 A ). A similar trend was observed in hFis1 protein levels as hFis1 protein levels 
were significantly increased in DXR-treated rats in comparison to the CTRL (251.7 ± 29.66% vs 
100%, p < 0.01). However, hFis1 protein levels were significantly decreased in DXR+MLT-treated 
rats in comparison to DXR-treated rats (144.6 ± 14.52% vs 251.7 ± 29.66%, p < 0.05) (Figure 3.9.7.2 
B). 
Figure 3.9.7.2: The effect of daily MLT administration on Drp1 and hFis1 protein levels during DXR-
induced cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. 
Drp1 and hFis1 protein levels were assessed in rat hearts using immunoblot analysis. Bar graphs show: A. 
Drp1 and B. hFis1 protein levels (normalized to total protein vs control). Values are expressed as a percentage 
of the control and presented as means ± SEM (n=minimum of 3), A: *p < 0.01 vs CTRL, #p < 0.001 vs DXR. 
B: *p < 0.01 vs CTRL, #p < 0.05 vs DXR. Abbreviations- CTRL: control; T CTRL: tumor control; V CTRL: 
vehicle control; DXR: doxorubicin; MLT: melatonin. 
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3.9.8 The effect of daily MLT administration on mitochondrial biogenesis during 
DXR-induced cardiotoxicity 
 
3.9.8.1 Immunoblot analysis of PGC-1α protein levels 
 
PGC-1α is a known marker of mitochondrial biogenesis. PGC-1α protein levels in rat heart tissue 
was quantified using immunoblot analysis. PGC-1α protein levels significantly decreased in DXR-
treated rats in comparison to the CTRL (41.02 ± 7.219% vs 100%, p < 0.01). PGC-1α protein levels 
significantly increased in MLT-treated rats in comparison to DXR-treated rats (106.3 ± 14.16% vs 
41.02 ± 7.219%, p < 0.001). Furthermore, PGC-1α protein levels were significantly increased in 
DXR+MLT-treated rats in comparison to DXR-treated rats (135.9 ± 4.917% vs 41.02 ± 7.219%, p < 
0.001) (Figure 3.9.8.1). 
 
 
 
 
 
 
 
 
 
Figure 3.9.8.1: The effect of daily MLT administration on PGC-1α protein levels during DXR-induced 
cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. PGC-
1α protein levels were assessed in rat hearts using immunoblot analysis. Bar graph indicates: PGC-1α protein 
levels (normalized to total protein vs control). Values are expressed as a percentage of the control and 
presented as means ± SEM (n=minimum of 3), *p < 0.01 vs CTRL, **p < 0.001 vs DXR, #p < 0.001 vs DXR. 
Abbreviations- CTRL: control; T CTRL: tumor control; V CTRL: vehicle control; DXR: doxorubicin; MLT: 
melatonin. 
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3.9.9 The effect of daily MLT administration on sirtuin activity during DXR-induced 
cardiotoxicity 
 
3.9.9.1 Immunoblot analysis of SIRT1 and SIRT3 protein levels 
SIRT1 and SIRT3 protein levels in rat heart tissue were quantified using immunoblot analysis. 
Mitochondria was isolated from rat heart tissue to assess SIRT3 and cell lysates were used to assess 
SIRT1. SIRT1 protein levels were significantly decreased in DXR-treated rats in comparison to the 
CTRL (50.97 ± 9.920% vs 100%, p < 0.05). Interestingly, SIRT1 protein levels were significantly 
increased in DXR+MLT-treated rats in comparison to DXR-treated rats (104.1 ± 10.65% vs 50.97 ± 
9.920%, p < 0.01) (Figure 3.9.9.1 A). However, no significant changes in SIRT3 levels occurred 
among the treated groups (Figure 3.9.9.1 B) 
 
Figure 3.9.9.1: The effect of daily MLT administration on SIRT1 and SIRT3 protein levels during DXR-
induced cardiotoxicity. Rats were either treated with MLT (6 mg/kg) or DXR (4 mg/kg) or both MLT and DXR. 
SIRT1 and SIRT3 protein levels were assessed in rat hearts using immunoblot analysis. Bar graphs show: A. 
SIRT1 and B. SIRT3 protein levels (normalized to total protein vs control). Values are expressed as a 
percentage of the control and presented as means ± SEM (n=minimum of 3), A: *p < 0.05 vs CTRL, #p < 0.01 
vs DXR. B: No significant changes. Abbreviations- CTRL: control; T CTRL: tumor control; V CTRL: vehicle 
control; DXR: doxorubicin; MLT: melatonin. 
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Chapter 4 
 
Discussion 
 
4.1 Introduction 
Although studies have been conducted on the protective role of melatonin (MLT) in DXR-induced 
cardiotoxicity, these studies largely lack information regarding the effect of MLT on mitochondrial 
function during DXR-induced cardiotoxicity. Moreover, there are few studies which use a tumor-
bearing model of DXR-induced cardiotoxicity. The aim of the current study was to determine the 
effect of melatonin on cell death, autophagy/mitophagy, mitochondrial fission and fusion, 
mitochondrial bioenergetics and biogenesis, sirtuin activity, cardiac function and tumor growth during 
DXR-induced cardiotoxicity. We hypothesized that pre-treatment with MLT will better preserve 
mitochondrial function during DXR-induced cardiotoxicity, thereby improving cardiomyocyte survival. 
Furthermore, we hypothesized that daily MLT administration would improve cardiac function whilst 
simultaneously exerting its oncostatic properties in our tumor-bearing rat model of DXR-induced 
cardiotoxicity. 
4.2 The effect of MLT on cell viability during DXR-induced cardiotoxicity 
It has been well established that DXR-induced cardiotoxicity terminates in the rapid loss of 
cardiomyocytes via various cell death pathways. In the current study, a concentration of 3 µM of 
DXR decreased cell viability in H9c2 cells and DXR at a 5 µM concentration equally decreased cell 
viability (Figure 3.1.1). Since the MTT reductive capacity is dependent on active mitochondrial 
reductase enzymes (dehydrogenases), the assay not only provides information on cell viability but 
also on mitochondrial viability in H9c2 cells. Previous work in our group demonstrated a significant 
decrease in cell viability in H9c2 cells treated with 3 µM of DXR for 24 hours (Sishi et al., 2013). In 
a clinical setting DXR is administered intravenously over a brief period of time at a dose of 60 - 75 
mg/m2 with plasma concentrations peaking at a range between 5 and 15 µM. Since ± 75% of DXR 
is bound by plasma proteins, the peak concentration of free DXR available to induce its apoptotic 
Stellenbosch University  https://scholar.sun.ac.za
78 | P a g e  
 
effects is between 1.25 and 3.75 µM (Liu, 2008). Since, 3 µM of DXR is within the clinically accepted 
range of 0.1 - 5 µM in vitro (Liu, 2008), this specific concentration was utilized in our study. 
There are only a few studies where the effect of MLT on H9c2 cells were investigated. In the current 
study, a concentration of 10 µM of MLT maintained cell viability to approximately control levels 
(Figure 3.1.2); therefore this concentration was used in further experiments. It has been 
demonstrated in clinical trials that plasma levels of MLT vary with age but are relatively maintained 
at < 10 pg/ml of plasma (Benloucif et al., 2008; Zeitzer et al., 2007). Although, a supra-physiological 
concentration of MLT was used in this study, there is no evidence supporting the toxicity of MLT at 
high doses (Venegas et al., 2012; Kasekar et al., 2014). Furthermore, the use of MLT at high doses 
has been shown to be essential in reaching adequate subcellular concentrations to exert its 
pharmacological effects (Venegas et al., 2012). 
No significant differences in viability were observed in cells treated with MLT either for a period of 
one hour or for 24 hours (Figure 3.1.3). Since, the plasma half-life of MLT is 20 to 50 minutes 
(Kasekar et al., 2014), it was expected that pre-treatment with MLT at a concentration of 10 µM for 
1 hour followed by DXR treatment would be sufficient to increase cell viability, however, a decrease 
in cell viability was observed (Figure 3.1.3). On the other hand, considering that H9c2 cells pre-
treated with MLT for 24 hours increased cell viability following DXR treatment at 3 µM for 24 hours 
(Figure 3.1.3), it is possible that a longer exposure time to MLT was required to increase the cells’ 
antioxidant capacity. In support of this notion, Mias and co-workers (2008), previously demonstrated 
that pre-incubation with MLT for 24 hours increased antioxidant catalase enzymes in a time-
dependent manner, with maximum levels of antioxidant catalase enzymes reached at 16 and 24 
hours. 
 To further confirm our findings, pre-treatment with MLT significantly increased the percentage of 
live cells whereas DXR alone decreased the percentage of live cells (Figure 3.2.1).  Therefore, based 
on these findings, MLT pre-treatment for 24 hours was chosen for subsequent experiments as we 
aimed to establish a time frame at which H9c2 cells will be offered maximal protection against DXR-
induced cardiotoxicity. 
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4.3 The effect of MLT on apoptosis during DXR-induced cardiotoxicity 
Caspases are cysteine aspartate proteins which tightly regulate cell turnover, differentiation and 
apoptosis (Thornberry, 1998; Elmore, 2007). Caspase-3 is a key downstream effector caspase and 
the cleavage of caspase-3 initiates apoptotic cell death (Elmore, 2007). Apoptosis is a common 
feature in the progression of DXR-induced cardiotoxicity. In the current study, the mechanism of 
cardiomyocyte apoptosis involved during the development of DXR-induced cardiotoxicity, was 
investigated. In our in vitro model of DXR-induced cardiotoxicity, cells pre-treated with MLT 
significantly reduced caspase3/7 activity (Figure 3.2.2). These results were further validated by 
immunoblot analysis of cleaved caspase-3 which revealed a significant increase in caspase-3 
cleavage following DXR treatment. However, pre-treatment with MLT appeared to protect the cells 
against the high degree of apoptotic activity induced by DXR as observed by the decrease in 
caspase-3 cleavage (Figure 3.2.3 A).  
Similarly, in our in vivo model of DXR-induced cardiotoxicity, cleaved caspase-3 levels were highly 
expressed in the heart tissue of DXR-treated rats. In contrast, in DXR+MLT-treated rats the 
expression of caspase-3 cleavage in rat heart tissue was significantly reduced (Figure 3.9.5.1 A). 
Previous work done in our group supports these findings, as caspase-3 cleavage increased in H9c2 
cells treated with DXR at 3 µM for 24 hours as well as in the hearts of mice which were treated with 
10 mg/kg of DXR (Sishi et al., 2013).   
Moreover, our results are in accordance with other studies which demonstrated that caspase-3 
activation increases during the heart failure stages of DXR-induced cardiotoxicity (Lou et al., 2005; 
Liu et al., 2008; Shen et al., 2016). Furthermore, MLT has been shown to significantly attenuate 
DXR-induced apoptosis in a murine model of DXR-induced cardiotoxicity without compromising the 
antineoplastic activity of DXR (Liu et al., 2002). MLT has also been shown to confer protection during 
myocardial ischemia/reperfusion injury by downregulating caspase-3 and cleaved caspase-3 
expression (Şehirli et al., 2013; Yu et al., 2014). 
A major mechanism by which DXR elicits its antitumor activity is via inducing double-stranded DNA 
breaks. Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme which is activated in response 
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to DNA strand breakage. PARP cleavage is initiated by active caspases 3 and 7 during apoptosis 
and has thus become a useful indicator of apoptotic activity (Gobeil et al., 2001). In both in vitro and 
in vivo models in the current study, PARP-cleavage significantly increased in response to DXR 
treatment (Figure 3.2.3 B and Figure 3.9.5.1 B). These results are in agreement with others studies 
which demonstrated that DXR also induces apoptosis via PARP-cleavage (Liu et al., 2008; Sishi et 
al., 2013). However, in our models of DXR-induced cardiotoxicity, pretreatment with MLT attenuated 
this effect by significantly decreased PARP-cleavage (Figure 3.2.3 B and Figure 3.9.5.1 B). In 
support of this finding, a recent study conducted by Chua et al. (2016) demonstrated that MLT and 
extendin-4 treatment decreased PARP cleavage in response to DXR treatment in H9c2 cells as well 
as in a rat model of cardio-renal syndrome.  
Taken together, the results in the current study clearly demonstrate that MLT pre-treatment confers 
cardiac protection by decreasing the expression of apoptotic cell death makers and increasing cell 
viability during DXR-induced cardiotoxicity. As cell death is central to the clinical limitation of DXR, 
the underlying mechanisms involved in the anti-apoptotic effects of MLT are worth investigating, as 
MLT could potentially serve as a cardioprotective agent in the context of DXR-induced cardiotoxicity. 
4.4 The effect of MLT on autophagy during DXR-induced cardiotoxicity 
Autophagy is characterized by the development of autophagosomes that engulf bulk cytoplasm, 
damaged organelles and other redundant cellular components before fusing with the lysosome, 
which results in mass proteolysis (Mizushima et al., 2008). Autophagy at basal levels in the heart is 
essential for maintaining cardiac contractility and function (Loos et al., 2011). This degradative 
process may also serve as a double-edged sword in the heart under conditions of stress: on the one 
hand, it serves as a significant renewal and pro-survival mechanism of cellular organelles and, on 
the other hand, if autophagy persists beyond a certain threshold, it may lead to cellular demise (de 
Meyer and Martinet, 2009; Gustaffson and Gottlieb, 2009).  
In our in vitro study, the effect of MLT on autophagic flux in conjunction with p62 levels were 
assessed during DXR-induced cardiotoxicity by the addition of bafilomycin A1 (autophagic inhibitor) 
to the various treatment groups. Autophagic flux is defined as a measure of autophagic degradation 
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activity (Loos et al., 2014). An increase in autophagic flux was observed in response to both DXR 
and MLT treatments as indicated by increases in LC3 II levels (Figure 3.3.1 A). In accordance with 
the increase in autophagic flux induced by DXR in our model, it was demonstrated in a rat model of 
chronic DXR cardiotoxicity, that increased autophagy contributed to a loss of cardiac myocytes and 
inhibition of autophagy with 3-methyladenine (3-MA), improved cardiac function, suggesting that 
autophagy is detrimental in the case of chronic DXR-induced cardiotoxicity (Lu et al., 2009).  
Interestingly, DXR+MLT treated cells responded with no change in LC3 II levels, which is indicative 
of an impairment in the autophagic machinery as the autophagosomes are not fusing with 
lysosomes. It is possible that MLT could possibly be suppressing the increase in autophagic flux 
induced by DXR. In support of this notion, in a model of liver ischemia/reperfusion (I/R) injury, 
autophagic flux was increased in response to I/R injury, but this was attenuated by MLT via inhibiting 
mTOR-dependent autophagy (Kang et al., 2014 ).  
Furthermore, the accumulation of autophagosomes observed in the DXR+MLT treated group does 
not specifically indicate autophagic cell death. In healthy cells, autophagosomes may also 
accumulate as a result of hindered processing of autophagosomes and this accumulation does not 
necessarily have to correspond with an increase in autophagic flux (Codogno and Meijer, 2005). In 
contrast to the unchanged LC3 II levels in DXR+MLT treated cells, p62 levels was significantly 
decreased in DXR+MLT treated cells (Figure 3.3.1 B), indicating that autophagosomal degradation 
is likely occurring in our model. These conflicting results may be attributed to the fact that autophagy 
is a dynamic process in which LC3 II and p62 levels are constantly changing in a time-dependent 
manner (Sahani et al., 2014).  
In our in vivo model, LC3 II and p62 levels in rat heart tissue were assessed but no conclusions on 
autophagic flux can be deduced from these results as fusion between autophagosomes and 
lysosomes was not inhibited in our in vivo model. The results demonstrated a significant increase in 
LC3 II levels in rat heart tissue of DXR, MLT and DXR+MLT-treated rats (Figure 3.9.6.1 A). In 
contrast to the decreased p62 levels in response to DXR+MLT treatment in our in vitro model, p62 
levels remained highly expressed in rat heart tissue of DXR+MLT-treated rats (Figure 3.9.6.1 B). 
Since p62 levels decreased in MLT-treated rats but significantly increased in DXR-treated rats, these 
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results may suggest that DXR is inhibiting autophagic degradation in our in vivo model of DXR-
induced cardiotoxicity.  
To fully elucidate the effect of MLT on autophagy during DXR-induced cardiotoxicity, the autophagic 
system should be assessed by characterizing each step of the autophagic process as a particular 
rate in order to accurately assess autophagosomal pool size and autophagic flux as described by 
Loos et al. (2014). Furthermore, cardiac autophagic flux in vivo can also be measured using 
chloroquine as described by Iwai-Kanai et al. (2008). 
4.5 The effect of MLT on Pink1 and PARKIN during DXR-induced cardiotoxicity 
Mitochondrial dysfunction is an apparent hallmark of DXR-induced cardiotoxicity. The selective 
elimination of damaged or malfunctioning mitochondria by autophagy is referred to as mitophagy 
which is an essential process for maintaining cellular homeostasis and mitochondrial quality control 
(Barthe et al., 2010). Pink1 and PARKIN are two critical proteins involved in the execution of 
mitophagy. Pink1 binds to damaged mitochondria and recruits PARKIN from the cytosol to initiate 
ubiquitination and mitophagic elimination (Chen and Dorn, 2013). Therefore, in the current study we 
investigated the effect of MLT pre-treatment on Pink1 and PARKIN protein levels during DXR-
induced cardiotoxicity as a potential indication for mitophagic events. 
Pink1 protein levels increased in response to both DXR and DXR+MLT treated cells (Figure 3.3.2 
A) suggesting that mitochondrial damage is occurring in both treatment groups. In contrast, Pink1 
protein levels significantly decreased in the heart tissue of DXR+MLT-treated rats but remained 
elevated in the heart tissue of DXR-treated rats (Figure 3.9.6.2 A) indicating that there is a higher 
degree of cardiac mitochondrial damage occurring in DXR-treated rats. Furthermore, PARKIN 
protein levels significantly increased in response to DXR+MLT treated cells, however PARKIN levels 
were severely diminished in DXR treated cells (Figure 3.3.2 B), suggesting that although DXR 
induces autophagy, it may simultaneously be impairing mitochondrial clearance by preventing the 
recruitment of PARKIN to damaged mitochondria. It has previously been demonstrated that DXR 
exposure can disrupt the clearance of damaged mitochondria by upregulation of p53 which inhibits 
the translocation of PARKIN to the mitochondrial outer membrane (Hoshino et al., 2012). 
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 Pre-treatment with MLT appears to restore the function of PARKIN protein (Figure 3.3.2 B). To 
support this finding, a recent study by Díaz-Casado et al. (2016), revealed that MLT restored the 
normal function and expression of Pink1 and PARKIN in a model of Parkinson-like disease. In 
contrast, PARKIN protein levels significantly increased in the heart tissue of DXR-treated rats (Figure 
3.9.6.2 B) suggesting that damaged mitochondria could possibly be eliminated by autophagy.  
The analysis of Pink1 and PARKIN protein levels is, however, insufficient to fully elucidate the effect 
of MLT pre-treatment on mitophagy during DXR-induced cardiotoxicity in the current study. These 
results need to be further supported with flow cytometry or microscopy using mitochondrial dyes that 
allow the assessment of mitochondrial cargo in autophagosomal vesicles (Rodriguez-Enriquez et 
al., 2002). Furthermore, it would be important to verify that changes in mitochondrial mass are as a 
result of autophagic activity and not decreased mitochondrial biogenesis. To ensure this, a critical 
autophagic regulator such as Beclin-1 should be knocked-down (Barthe et al., 2010). 
4.6 The effect of MLT on mitochondrial ROS production during DXR-induced 
cardiotoxicity 
Mitochondria are abundant in cardiac tissue, constituting about 45% of the myocardial volume 
(Marin-Garcia et al., 2001) in comparison with other tissues. The abundance of mitochondria in the 
heart is mainly attributed to the high energy demand of the heart. DXR targets mitochondria and 
accumulates in these organelles at concentrations 100-fold higher than in plasma (Tokarska –
Schlattner et al., 2007). One major and widely investigated hypothesis of DXR-induced cardiotoxicity 
is based on the generation of free radicals, which induces oxidative stress (Olson et al., 1981). DXR 
is known to induce free radical formation in two major ways: (i) through utilizing cellular 
oxidoreductases (NADH and NADH dehydrogenase of complex I, NADPH and cytochrome P-450 
reductases or endothelial nitric oxide synthase); and (ii) by forming complexes with iron in plasma 
(Tokarska –Schlattner et al., 2006; Doroshow et al., 1980; Minotti et al., 1999). Furthermore, DXR is 
known to be involved in a 'redox-cycling' process, thereby inducing a vicious cycle of free radical 
production (Davies and Doroshow, 1986; Zhu et al., 2016). During mitochondrial respiration, free 
radicals are formed and therefore the heart, in particular, is highly susceptible to DXR-induced 
oxidative damage as it is abundant in mitochondria, which are both sources and targets for ROS 
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(Doroshow, 1983; Octavia et al., 2012). To further exacerbate the free radical production induced by 
DXR, the heart has a limited antioxidant defense systems when compared to other tissues 
(Doroshow et al., 1980; Quiles et al., 2002).  
MLT’s potent free-radical scavenging properties have been well documented. MLT appears to be 
superior to conventional anti-oxidants as its metabolites, namely, AFMK and AMK, have also been 
reported to possess free radical scavenging properties, creating a free radical scavenging cascade 
(Tan et al., 2001; Galano et al., 2013). MLT in turn acts to increase the organism’s antioxidant 
defense system as both physiological and pharmacological doses of MLT have resulted in increased 
gene expression and activities of various cellular antioxidants (GPx, GRd, SOD and CAT) (Antolin 
et al., 1996; Reiter et al., 2000; Fischer et al., 2013). Furthermore, the most unique property of MLT, 
which is absent in most antioxidants, is that it does not undergo redox cycling (Tan et al., 2000). 
Most antioxidants tend to become pro-oxidants when encountered with free radicals, further 
promoting oxidation and free radical production. Since MLT is an electron-rich molecule, it interacts 
with free radicals and forms stable end products which are excreted in the urine (Tan et al., 2000). 
Hence, MLT is considered to be a terminal or suicidal antioxidant distinguishing it from conventional 
antioxidants (Tan et al., 2000). 
Therefore, in the current study the effect of MLT on free radical production induced by DXR was 
investigated in vitro. It was demonstrated in our results that DXR treated H9c2 cells did not 
significantly increase ROS generation in comparison to the CTRL (Figure 3.4.1 A). This result could 
possibly be due to the fact that DXR increases the mean intensity of H2DCFDA in a concentration-
dependent manner during DXR-induced cardiotoxicity (Chang et al., 2011). However, pre-treatment 
with MLT significantly attenuated ROS generation in comparison to the DXR treated cells (Figure 
3.4.1 A).  
Furthermore, apart from increasing hydroxyl radicals and hydrogen peroxide, DXR is also known to 
increase reactive nitrogen species (RNS) (Lai et al., 2011). However, RNS is not well detected by 
H2DCFDA (Kalyanaraman et al., 2012). The use of H2DCFDA as a fluorescent probe to measure 
hydrogen peroxide and other oxidants is debatable since H2DCFDA does not directly react with 
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hydrogen peroxide to form the fluorescent product, DCF (Kalyanaraman et al., 2012). Therefore, 
DCF fluorescence should rather be used as a redox indicator probe (for review see Kalyanaraman 
et al., 2012). In contrast, MitoSox Red is a more suitable indicator of intracellular oxidants 
(Kalyanaraman et al., 2012). Mitochondrial ROS generation significantly increased in response to 
DXR treatment in comparison to the CTRL, whereas pre-treatment with MLT for 24 hours 
significantly decreased mitochondrial ROS generation in comparison to DXR treated cells (Figure 
3.4.1 B). These results suggest that pre-treatment with MLT induced a shift of mitochondria away 
from the oxidative state induced by DXR. The reduction in oxidative stress induced by MLT is likely 
attributed to its potent free radical scavenging properties. These results are in accordance with other 
studies which demonstrated that MLT reduces oxidative stress during DXR-induced cardiotoxicity 
(Dziegiel et al., 2002; Balli et al., 2004; Eser et al., 2006). 
4.7 The effect of MLT on mitochondrial membrane potential during DXR-induced 
cardiotoxicity 
MLT has been reported to protect the mitochondria by preventing cardiolipin oxidation, which would 
otherwise promote mitochondrial transition pore opening (mPTP), resulting in cell death (Paradies 
et al., 2010). Furthermore, MLT’s preferential juxtaposition to the lipid molecules in membrane lipid 
layers protects biological membranes against lipid peroxidation (Reiter et al., 2014). In the current 
study, MLT treatment alone significantly increased mitochondrial membrane potential in comparison 
to the CTRL (Figure 3.5.1). Considering that cardiac cells have a high energy demand, the high 
mitochondrial membrane potential observed is required for ATP production (Klingenberg and 
Rottenberg, 1977) and could have resulted from MLT scavenging free radicals, which are produced 
during basal mitochondrial respiration. Furthermore, pre-treatment with MLT restored mitochondrial 
membrane potential reduced by DXR (Figure 3.5.1). This result is consistent with earlier reports that 
indicated that MLT was able to alleviate reduced mitochondrial potential induced by DXR (Song et 
al., 2012; Guven et al., 2016). Specifically, in the context of DXR-induced cardiotoxicty, mitochondria 
in DXR treated myocytes exhibited a collapse in mitochondrial membrane potential, which was 
prevented with MLT pre-treatment (Xu and Ashraf, 2002). 
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Increases in oxidative stress is strongly associated with a loss in mitochondrial membrane potential 
and acts as a trigger for mitophagy (Kim et al., 2007). In fact, changes in mitochondrial redox state 
and mitochondrial membrane potential have been shown to precede mitochondrial dysfunction 
during DXR-induced cardiotoxicity (Kuznetsov et al., 2011). A potential mechanism by which DXR 
disrupts mitochondrial membrane potential is via its binding to cardiolipin. DXR tends to accumulate 
in mitochondria owing to its cationic nature that has a high affinity for the negatively charged 
cardiolipin, a major phospholipid component in the inner mitochondrial membrane (Goormaghtigh et 
al., 1980). The binding of DXR to cardiolipin results in oxidation of this phospholipid, which leads to 
the formation of an irreversible complex. Cardiolipin forms the structural basis for maintaining 
mitochondrial membrane potential as demonstrated previously (Paradies et al., 2014; Jiang et al., 
2000). In contrast, a deficiency in cardiolipin was shown to increase mitochondrial membrane 
potential and reduces DXR-induced oxidative stress in human B-Lymphocytes (Aryal and Rao, 
2016). 
4.8 The effect of MLT on mitochondrial morphology during DXR-induced 
cardiotoxicity 
Since pre-treatment with MLT attenuated mitochondrial ROS formation and restored mitochondrial 
membrane potential, it was crucial to further examine the effect that MLT pre-treatment has on 
dynamic changes in mitochondrial morphology. The CTRL and MLT treated cells maintained 
elongated-shaped mitochondria and an interconnected mitochondrial networks around the 
perinuclear region of the cell (Figure 3.6.1.1). However, mitochondria were fragmented and 
spherical-shaped in response to DXR treatment and appeared further dispersed from the perinuclear 
region of the cell (Figure 3.6.1.1). MLT pre-treatment appeared to significantly reduce the amount of 
spherical-shaped mitochondria as most cells maintained elongated-shaped mitochondria and an 
interconnected mitochondrial network (Figure 3.6.1.1).  
The form factor analysis performed on the images provided information on the aspect ratio of 
mitochondria which is the ratio between the major and minor axes of an ellipse equivalent to the 
shape of mitochondria and the degree of branching of the mitochondrial network (Mortiboys et al., 
2008). The observations made regarding the morphology of mitochondria during live-cell imaging 
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corresponded with the form factor analysis as the major/minor aspect ratio and the degree of 
mitochondrial branching was significantly reduced in DXR treated cells in comparison to cells which 
were pre-treated with MLT (Figure 3.6.1.2). These results suggest that pre-treatment with MLT 
improves mitochondrial morphology during DXR-induced cardiotoxicity.  
However, an assessment of mitochondrial morphology is only a snapshot of the dynamic changes 
in mitochondrial morphology and should be carefully used as indicator for mitochondrial fission and 
fusion (Galloway et al., 2012). To support this notion, it was indicated in a previous study that 
mitochondria became elongated under nutrient starvation conditions via the activation of 
mitochondrial fission proteins (Rambold et al., 2011). Therefore, in the current study we investigated 
the effect of MLT on mitochondrial fission and fusion proteins during DXR-induced cardiotoxicity. 
4.9 The effect of MLT on mitochondrial fission and fusion during DXR-induced 
cardiotoxicity 
In mammalian cells, mitochondrial fusion is a process governed by Mitofusin proteins 1 and 2 (Mfn1 
and Mfn2) as well as Optic Atrophy 1 (OPA1).  Mitofusin is localized to the outer mitochondrial 
membrane and facilitates the binding of two distinct mitochondria during early stages of 
mitochondrial fusion (Lee et al., 2007; Scott and Youle, 2010). OPA1 is a dynamin family GTPase 
which is localized to the inner mitochondrial membrane and intermembrane space. OPA1 promotes 
fusion of the inner mitochondrial membrane and regulates the morphology of mitochondrial cristae 
(Lee et al., 2007; Scott and Youle, 2010). Eight isoforms of OPA1 have been identified, the most 
dominant isoforms are L-OPA1 (Long-form of OPA1) and S-OPA1 (Short-form of OPA1) (Song et 
al., 2007; Scott and Youle, 2010). On the other hand, mitochondrial fission is controlled by hFis1 and 
Drp1. hFis1 is located in the outer mitochondrial membrane and it forms protein-protein interaction 
sites which protrude into the cytosol (Scott and Youle, 2010). Drp1 is mainly located in the cytosol 
and upon fission Drp1 is recruited to the mitochondria via hFis1. When Drp1 interacts with hFis1 at 
fission sites, a collar around the mitochondrion is formed. Constriction of the collar leads to a 
separation of the outer mitochondrial membrane yielding two independent organelles (Scott and 
Youle, 2010).   
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In our study, the expression of L-OPA1 and S-OPA1 isoforms remained unchanged in vitro and in 
vivo in response to various treatments (Figure 3.6.2.2 and Figure 3.9.7.1 C). Indeed, a combination 
of L-OPA1 and S-OPA1 isoforms are critical for mitochondrial fusion activity (Song et al., 2007). 
However, L-OPA1 has two cleavage sites (S1 and S2) which can be cleaved either by YME1L, an 
ATP-dependent metalloprotease or OMA1, a zinc-metalloprotease (McBride and Sounbannier, 
2010; Thomas et al., 2014) to generate S-OPA1. Under basal conditions, YME1L cleaves L-OPA1 
at S2 and generates fusion-competent cells (Song et al., 2007; Thomas et al., 2014). However, in 
response to stress, OMA1, cleaves L-OPA1 at S1, which inhibits mitochondrial membrane fusion 
(Head et al., 2009; Thomas et al., 2014). Hence, in the current study it remains unknown if the S-
OPA1 band observed (Figure 3.6.2.2 and Figure 3.9.7.1 C) corresponds to the cleavage by YME1L 
or OMA1. To fully elucidate the role of OPA1 during mitochondrial fusion in our model, the mRNA 
content from treated cells should be analyzed by qRT-PCR for changes in expression of YME1L and 
OMA1. Nonetheless, OPA1 has been shown to be dependent on Mfn1 to promote mitochondrial 
fusion (Cipolat et al., 2004).  
In both in vitro and in vivo models, pre-treatment with MLT significantly increased the expression of 
mitofusin proteins, which was inhibited by DXR (Figure 3.6.2.1 and Figure 3.9.7.1). Furthermore, 
MLT pre-treatment significantly attenuated the expression of hFis1 and Drp1 proteins increased by 
DXR both in vitro and in vivo (Figure 3.6.2.3 and Figure 3.9.7.2). Thus, the results obtained in the 
current study suggest that DXR is disrupting mitochondrial fusion and favoring mitochondrial fission 
as indicated by reduced mitofusin protein (Mfn1 and Mfn2) expression as well as increased 
mitochondrial fission protein (Drp1 and hFis1) expression. In contrast, pre-treatment with MLT 
reversed the changes in expression of mitochondrial fission and fusion proteins, favoring 
mitochondrial fusion during DXR-induced cardiotoxicity.  
It was reported in a previous study which investigated the role of mitochondrial fusion and fission in 
a rat model of DXR-induced hepatic toxicity, that DXR reduced the content of OPA1, Mfn1 and Mfn2, 
but had no effect on Drp1 and hFis levels (Dirks-Naylor et al., 2014). In contrast, co-administration 
of DXR with mdivi-1, a mitochondrial fission inhibitor, prevented detrimental effects of DXR via 
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reduced expression of Drp1 and also prevented an increase in the levels of both p53 and Erk 1/2, in 
a model of DXR-induced cardiotoxicity (Gharanei et al., 2013). Furthermore, SIRT3-dependent 
activation of OPA1 contributed to the preservation of mitochondrial networking by favoring 
mitochondrial fusion and thus protected cardiomyocytes from DXR-induced cell death (Scher et al., 
2007).  
The variation in results is likely owing to various models and experimental methods used to assess 
mitochondrial fission and fusion proteins. In our study, mitochondrial isolations from H9c2 cells and 
rat heart tissue were used to assess the protein levels of mitochondrial fission and fusion proteins 
whereas other studies tend to use cell or tissue lysates. The use of cell or tissue lysates may not 
clearly indicate if there are changes in expression of proteins such as Drp1, since Drp1 is located in 
the cytosol and whether it is recruited to the mitochondria upon fission. There are also a limited 
number of studies where the effect of MLT on mitochondrial fission and fusion in the context of DXR-
induced cardiotoxicity were investigated. MLT has, however, been shown to influence the expression 
of mitochondrial fission and fusion proteins (Wappler et al., 2012; Stacchiotti et al., 2014; Kang et 
al., 2016). In a model of hepatotoxicity, MLT attenuated the reduced effect of Drp1 and Mfn2, Pink1, 
PARKIN and PGC1-α induced by carbon tetrachloride, suggesting that MLT protects against liver 
fibrosis via upregulation of mitophagy and mitochondrial biogenesis (Kang et al., 2016).  
In cardiac cells, mitochondrial fission and fusion are critical processes, which adapt the morphology 
of mitochondria to meet the high metabolic needs of the heart. Mitochondrial fusion is a common 
feature of actively respiring cells. The interconnected mitochondrial network formed during fusion, 
allows for the distribution of respiratory enzymes and metabolites throughout the entire mitochondrial 
compartment of the cell (Westermann, 2012). The high energy demand of the heart is satisfied during 
mitochondrial respiration which generates ATP, of which more than 90% is utilized by 
cardiomyocytes (Tokarska –Schlattner et al., 2006). The underlying molecular mechanisms by which 
DXR induces a bioenergetic decline in the heart have been well documented in various studies (for 
review see Tokarska –Schlattner et al., 2006) however, less is known about MLT’s effects in the 
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context of DXR-induced cardiotoxicity. Therefore, in the current study we investigated the effect of 
MLT on mitochondrial respiration in H9c2 cells, during DXR-induced cardiotoxicity. 
4.10 The effect of MLT on mitochondrial bioenergetics and biogenesis during DXR-
induced cardiotoxicity 
Pre-treatment with MLT caused a significantly increase in cellular ATP levels (Figure 3.7.1.2) but 
had no effect on basal respiration and ATP-linked respiration in H9c2 cells (Figure 3.7.1.1 A and B). 
Furthermore, pre-treatment with MLT increased the electron transport system (ETS) capacity and 
mitochondrial spare respiratory capacity (MSRC) which were reduced by DXR treatment (Figure 
3.7.1.1 C and D). The ETS capacity is an unstable state of respiration where the addition of a 
mitochondrial uncoupler (FCCP) collapses the inner membrane gradient and stimulates increased 
respiration. Therefore, the ETS capacity is indicative of the substrate oxidation and the maximum 
activity of the electron transport system that is achievable by the cells during steady state ADP levels 
(Rose et al., 2014).  The MSRC is indicative of the amount of extra ATP that can be produced by 
oxidative phosphorylation during an increase in energy demand (Desler et al., 2012). Considering 
that pre-treatment with MLT stabilized mitochondrial membrane potential and increased the ETS 
capacity in H9c2 cells, it is suggested that MLT maintains mitochondrial function via attenuating the 
damaging effects of DXR on the electron transport chain. The increase in MSRC observed in cells 
pre-treated with MLT indicates that MLT is compensating for the loss of ATP induced by DXR. 
Furthermore, MLT treatment alone maintained cellular ATP at basal levels suggesting that MLT 
elicits a protective effect on the mitochondria during stressful conditions such as DXR-induced 
cardiotoxicity.  
Interestingly, MLT was also found to influence mitochondrial respiratory complexes I and IV in brain 
and liver tissues (Martin et al., 2000). In a model of septic heart injury, MLT increased complex IV 
activity and improved cardiac function (Zhang et al., 2013). In fact, chronic oral administration of 
MLT increased ATP content of hepatocytes isolated from old Wistar rats (Tresguerres et al., 2012). 
However, studies where the direct effect of MLT on mitochondrial respiration and ATP generation 
during DXR-induced cardiotoxicity are investigated, are lacking. Furthermore, the exact mechanisms 
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by which MLT stabilizes mitochondrial respiration and increases ATP content in cells are not well 
understood. However, it is suggested in most studies that these effects may be attributed to MLT’s 
antioxidant activity as well as its ability to reduce lipid peroxidation and improve mitochondrial 
membrane potential as observed in our study. 
DXR has a high affinity to cardiolipin, the binding of DXR to cardiolipin leads to the formation of an 
irreversible complex inhibiting oxidative phosphorylation as it renders cardiolipin incapable of acting 
as a cofactor for mitochondrial respiratory enzymes (Goormaghtigh et al., 1980; Goormaghtigh et 
al., 1986). In addition, as the inner mitochondrial membrane represents a critical site for DXR 
accumulation, the respiratory chain is vulnerable to the toxic effects of DXR. In particular, it was 
demonstrated in studies which aimed to determine the sensitivity of respiratory complexes, that DXR 
was mainly located in complexes I, III, and IV, with a specific vulnerability for complexes I (NADH 
dehydrogenase) and IV (cytochrome c oxidase) (Goormaghtigh et al., 1986; Nicolay  et al., 1987; 
Marcillat et al., 1989).  
Various signaling pathways that regulate the enzymatic capacity for fatty-acid β-oxidation, 
mitochondrial oxidative phosphorylation (OXPHOS) as well as mitochondrial biogenesis and function 
appear to converge at the transcriptional co-activator peroxisome proliferator-activated receptor-
gamma coactivator-1alpha (PGC-1α). PGC-1α has been shown to directly influence and modulate 
the activity of several mitochondrial genes at transcriptional level (Lin et al., 2005; Fernandez-Marcos 
and Auwerx, 2011). It was demonstrated in PGC-1α deficient mice that this co-activator diminished 
postnatal growth of organs abundant in mitochondria such as the heart and was also necessary for 
the normal expression of various mitochondrial genes (Leone et al., 2005). Cardiac remodeling is 
apparent in the DXR-challenged heart as DXR is known to initiate a switch in metabolic substrate 
utilization from fatty acids to glucose (Tokarska –Schlattner et al., 2005; Tokarska –Schlattner et al., 
2006) and this subsequently leads to inefficient ATP production as also demonstrated in the our 
study (Figure 3.7.1.2). Furthermore, DXR has been shown to inhibit the expression of PGC-1α, 
leading to the suppression of adipogenesis and resulting in the impaired import of glucose mediated 
through glucose transporter type 4 (GLUT4) (Arunachalam et al., 2013). Interestingly, MLT has also 
been shown to influence the expression of PGC-1α (Guven et al., 2016; Guo et al., 2014).  
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In our study, the effect of MLT on PGC-1α expression was investigated during DXR-induced 
cardiotoxicity. Pre-treatment with MLT significantly restored PGC-1α expression that was 
significantly attenuated in response to DXR treatment in both H9c2 cells and rat heart tissue (Figure 
3.7.3.1 and Figure 3.9.8.1).   In support of our findings, Guven et al. (2016) recently reported that 
MLT given with DXR increased PGC-1α and AMPK levels which was reduced by DXR in mouse 
fibroblasts. Moreover, adult mice hearts deficient in both PGC-1α and PGC-1β demonstrated a 
mitochondrial cristae-stacking abnormality suggestive of a phospholipid abnormality as described in 
humans with Barth syndrome which is characterized by genetic defects in cardiolipin synthesis (Lai 
et al, 2014). Genetic profiling in these mice hearts revealed reduced expression of the gene encoding 
CDP-diacylglycerol synthase 1, an enzyme that catalyzes the proximal step in cardiolipin 
biosynthesis (Lai et al, 2014) suggesting that PGC-1α influences the biosynthesis of cardiolipin. 
Since, DXR directly oxidizes cardiolipin it may also be disrupting the synthesis of cardiolipin and ATP 
production via the suppression of PGC-1α in our model.  
Furthermore, mitochondrial biogenesis is strongly correlated with mitochondrial fission and fusion. 
PGC-1α has been reported to influence the activity of mitochondrial fission and fusion proteins. In 
particular, PGC-1α stimulates the expression of Mfn2 under conditions characterized by enhanced 
energy expenditure (Cartoni et al., 2005; Soriano et al., 2006; Zorano, 2009) such as DXR-induced 
cardiotoxicity. On the other hand, Mfn2 loss of function has been correlated with the reduced 
stimulatory effect of PGC-1α on mitochondrial membrane potential (Soriano et al., 2006). 
Furthermore, downregulation of PGC-1α leads to increased expression of the mitochondrial fission 
protein, Drp1 (Guo et al., 2015). DXR attenuated the expression of Mfn2 and increased the 
expression of Drp1 in both in vitro and in vivo models in our study suggesting that DXR could possibly 
be inducing these effects via reducing PGC-1α. In summary, apart from MLT’s antioxidant activity, 
pre-treatment with MLT could also be increasing the expression of mitochondrial fusion proteins and 
promoting cardiolipin synthesis via PGC-1α activation, thus maintaining mitochondrial membrane 
potential and an interconnected fused mitochondrial network which subsequently facilitates ATP 
production during DXR-induced cardiotoxicity.  
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4.11 The effect of MLT on sirtuin activity during DXR-induced cardiotoxicity 
It has been previously demonstrated that sirtuin 1 (SIRT1) is an important upstream regulator of 
PGC-1α signaling (Cantó and Auwerx, 2009; Wang et al., 2015; Guo et al., 2015).  The sirtuins are 
a family of proteins that act predominantly as nicotinamide adenine dinucleotide (NAD)-dependent 
deacetylases (Sack and Finkel, 2012). SIRT1 and SIRT2 can be found in the cytosol, SIRT3, SIRT4 
and SIRT5 are localized to the mitochondria and, SIRT6 and SIRT7 are nuclear proteins (Sack and 
Finkel, 2012).  
In our study, pre-treatment with MLT restored the expression of SIRT1 and SIRT3 which were 
reduced by DXR in H9c2 cells (Figure 3.8.1.1). Interestingly, MLT treatment alone reduced the 
expression of SIRT1 but not SIRT3 (Figure 3.8.1.1). It is possible that MLT increases SIRT1 
expression under conditions of stress such as DXR-induced cardiotoxicity. Furthermore, pre-
treatment with MLT increased the expression of SIRT1 in rat hearts reduced by DXR, however no 
changes in SIRT3 expression was observed in our in vivo model (Figure 3.9.9.1). In support of our 
findings, it was reported in recent studies that SIRT1 expression, stimulated by resveratrol, reduced 
DXR-induced cardiomyocyte apoptosis and ROS production and that these protective effects were 
attenuated when SIRT1 was inhibited by nicotinamide (Danz et al., 2009; Ruan et al., 2015; Liu et 
al., 2016). DXR has also been demonstrated to reduce SIRT3 expression in primary cultures of 
cardiomyocytes and in mouse hearts (Pillai et al., 2016). SIRT3 overexpression protected the heart 
from mitochondrial DNA damage and cardiomyocyte cell death induced by DXR (Pillai et al., 2016). 
Furthermore, the authors reported that SIRT3 deficient mice developed cardiac hypertrophy and 
died during the course of DXR treatment suggesting that SIRT3 activation protects the heart during 
DXR-induced cardiotoxicity (Pillai et al., 2016).  
In the heart, SIRT1 inhibits the expression of pro-apoptotic proteins Bax and cleaved caspase-3 and 
enhances the expression of anti-apoptotic protein Bcl-xL (Hsu et al., 2010), suggesting that 
activation of SIRT1 promotes cardiomyocyte survival during heart failure. A study conducted by Lu 
et al. (2014), revealed that SIRT1 expression was reduced in humans with advanced heart failure. 
Interestingly, SIRT3 expression was found to be elevated during energy depletion in the heart to 
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compensate for the loss of ATP by regulating free fatty acid metabolism to meet the high ATP 
demand in the heart (Ingwall et al., 2009; Pillai et al., 2010). Supporting this notion, the ATP content 
in the hearts of SIRT3 deficient mice was significantly reduced suggesting that SIRT3 plays a crucial 
role in regulating ATP production (Ahn et al., 2008). Moreover, SIRT3 reduced oxidative stress by 
deacetylation of lysine residues on superoxide dismutase 2, a crucial mitochondrial antioxidant (Qiu 
et al., 2010). SIRT1 and SIRT3 expression is critical for maintaining cardiac function, therefore, in 
the current study the effect of MLT on SIRT1 and SIRT3 expression during DXR-induced 
cardiotoxicity was investigated.  
There is however a lack of information to support the role of MLT on sirtuin activity in the context of 
DXR-induced cardiotoxicity. However, in a model of myocardial ischemia/reperfusion injury, MLT 
has been shown to improve cardiac function, reduce apoptotic protein expression, myocardium 
superoxide generation, malondialdehyde levels, and increase myocardium superoxide dismutase in 
a SIRT1 dependent manner as these protective effects were attenuated in the presence of a MLT 
receptor antagonist, luzindole, or SIRT1 inhibitor, EX527 (Yu et al., 2014). It was found in another 
study that MLT facilitated adipose-derived mesenchymal based therapy in myocardial infarction by 
promoting the survival of these stem cells via SIRT1 signaling (Han et al., 2016). It is therefore 
suggested that MLT elicits anti-apoptotic and antioxidant effects via modulating SIRT1 activity in the 
heart. There are however no evidence for the role of MLT on SIRT3 expression in the heart. In a 
model of hepatotoxicity, MLT has been shown to increase superoxide dismutase 2 via upregulation 
of SIRT3 (Chen et al., 2015). It was revealed in a recent study that MLT enhanced SIRT3 activity 
and increased the binding of Foxo3a to superoxide dismutase 2 and catalase; thereby reducing 
oxidative stress during ovarian aging (Song et al., 2016). It is therefore evident from these studies 
that MLT enhances the expression of mitochondrial antioxidants via modulating SIRT3 activity during 
oxidative stress. 
In summary, our results suggest that pre-treatment with MLT during DXR-induced cardiotoxicity 
appears to influence both SIRT1 and SIRT3 activity. It is likely that MLT, apart from inducing its free 
radical scavenging activity during oxidative stress, modulates the activity of SIRT1 and SIRT3 which 
subsequently stimulates mitochondrial antioxidant defense systems in the heart to counteract the 
Stellenbosch University  https://scholar.sun.ac.za
95 | P a g e  
 
increase in mitochondrial ROS production induced by DXR as observed in our in vitro model. 
Furthermore, the underlying mechanisms of MLT’s anti-apoptotic effects in H9c2 cells and in rat 
heart tissues exposed to DXR, is possibly associated with the upregulation of SIRT1 during DXR-
induced cardiotoxicity. Since SIRT1 has emerged as an upstream regulator of PGC-1α, MLT could 
possibly be eliciting its protective mitochondrial effects such as promoting mitochondrial fusion, 
maintaining mitochondrial membrane potential and increasing ATP production via a SIRT1 and 
PGC-1α dependent signaling pathways. However, to validate the effect of MLT pre-treatment on 
SIRT1 activity during DXR-induced cardiotoxicity, a MLT receptor antagonist such as luzindole or a 
SIRT1 inhibitor such as EX527 needs to be used in future studies. 
 
4.12 The effect of daily MLT administration on cardiac function, animal body weight 
and tumor growth during DXR-induced cardiotoxicity 
To establish a tumor-bearing rat model of acute DXR cardiotoxicity, female Sprague Dawley rats 
(16-18 weeks old), received DXR (3 intraperitoneal injections of 4 mg/kg at 3-day intervals, 12 mg/kg 
cumulative dose) or received MLT (6 mg/kg) daily in their drinking water. The treatment doses used 
in the current study were chosen based on previous work which showed that MLT treatment (6 
mg/kg/day) for two weeks prevented the cardiotoxic side effects of DXR (12 mg/kg) (Balli et al., 
2004). It has been previously shown that an optimal accumulative dose of 12.45 mg/kg of DXR is 
needed to induce congestive heart failure in Wistar rats (Spivak et al., 2013) and doses which 
exceeded 12.45 mg/kg caused death. In the clinical setting, patients receive DXR in multiple doses 
between 50-75 mg/m2 over several months with a cumulative maximum of 450 mg/m2, which is 
equivalent to approximately 12 mg/kg (Yi et al., 2005), therefore the dose of DXR used in our study 
is also clinically relevant. The method of administering MLT to rats via their drinking water has been 
well established and used in various studies (Nduhirabandi et al., 2011; Stacchiotti et al., 2014; 
Moreira et al., 2015). Since, MLT is usually administered over a long period of time, methods such 
as oral gavage or intra-peritoneal injections can induce a stress-response in the animals over time. 
However, a major limitation of administering MLT to rats via their drinking water is that the exact 
dose of MLT received by each individual rat is unknown. 
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In the clinical oncology setting, two major types of DXR cardiotoxicity are evident. Acute 
cardiotoxicity occurs promptly during or shortly after treatment with DXR and manifests as 
myopericarditis, palpitations, paroxysmal non-sustained supraventricular tachycardia and acute-left 
ventricular failure, although rare (Takemura and Fujiwara, 2007). The incidence of acute 
cardiotoxicity is approximately 11% and symptoms are reversible with appropriate treatment 
(Takemura and Fujiwara, 2007; Shakir and Rasul, 2009; Chatterjee et al., 2010). Chronic 
cardiotoxicity occurs within 30 days of the last administered dose, but may even occur 6-10 years 
after the last treatment and manifests as irreversible cardiomyopathic changes leading to congestive 
heart failure with a poor prognosis. The incidence of DXR-induced cardiomyopathy is approximately 
1.7% and is greatly dependent on the accumulative dose of DXR (Takemura and Fujiwara, 2007; 
Chatterjee et al., 2010). Both acute and chronic administration appear to limit the dose of DXR used 
to treat cancer patients as a result of its cardiotoxic effects. In the current study an acute model of 
DXR-induced cardiotoxicity was used to assess the effect of daily MLT administration on cardiac 
function during DXR-induced cardiotoxicity.   
Cardiac function was significantly improved in rats treated with MLT and DXR as shown by the 
significant increase in cardiac output, total work performance and stroke volume compared to rats 
that received DXR only (Figure 3.9.4). Although there was a reduction in cardiac output and stroke 
volume in DXR-treated rats, this was not significant when compared to the CTRL. However, a 
significant decrease in the total work performance of the heart was observed in DXR-treated rats in 
comparison to the CTRL (Figure 3.9.4). No significant changes in heart rate were observed among 
the treated groups.  It was recently demonstrated that DXR significantly decreased stroke volume, 
ejection fraction, cardiac output, and left ventricular systolic pressure in mouse hearts (Mitry and 
Edwards, 2016). In another study, it was demonstrated that DXR significantly reduced arterial 
pressure and left ventricular fractional shortening as well as inducing a significant accumulation of 
ascites; these cardiomyopathy associated changes were ameliorated with MLT treatment 
(Morishima et al., 1998). Liu and co-workers reported a 50% reduction in heart rate and coronary 
flow which was reversed with MLT treatment in perfused mouse hearts treated with DXR (Liu et al., 
2002). Although the dose of DXR (12 mg/kg) used in this study induced a decline in cardiac function, 
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the dose was not fatal as none of the animals died during the course of this study. Furthermore, a 
significant reduction in total body weight and in heart weight were observed in DXR-treated rats 
which was attenuated in DXR+MLT treated rats (Figure 3.9.1 and Figure 3.9.3). In support of these 
findings, MLT was shown to attenuate DXR-induced body weight loss in male Sprague Dawley rats 
(Kim et al., 2005) and attenuate heart weight reduced by DXR (Morishima et al., 1998). Furthermore, 
DXR has been shown to induce marked atrophy of the hearts in a juvenile mouse model (Zhu et al., 
2008). 
There are however no studies where the effect of MLT on cardiac function and cancer during DXR-
induced cardiotoxicity are assessed in a tumor-bearing rat model.  Therefore, the effect of MLT 
during DXR-induced cardiotoxicity is rarely investigated in a more clinically relevant animal model. 
In the current study, tumors cells were inoculated in the mammary fat pad of rats to simulate a model 
of breast cancer to investigate the effect of MLT on tumor growth during DXR-induced cardiotoxicity. 
Tumors were palpable and decreased in volume in response to MLT treatment alone (Figure 3.9.2). 
These results suggest that MLT treatment induces an oncostatic effect. Interestingly, tumors were 
palpable and could not be measured in all ten animals in the DXR+MLT treated group by day 10 
(Figure 3.9.2), which suggests that MLT enhances the anti-cancer activity of DXR and the 
combination of DXR+MLT treatment has a more rapid oncostatic effect on tumor growth than DXR 
treatment alone. 
The effect of MLT on cancer has been widely investigated. A previous study demonstrated that MLT 
itself inhibits the growth of human breast cancer cells. In addition, the combination of MLT and DXR 
further reduced the growth of human breast cancer cells, suggesting that MLT improved the 
antitumor activity of DXR (Kim et al., 2005). In a clinical trial conducted by Lissoni and co-workers, 
MLT in combination with chemotherapy was shown to significantly increase the overall tumor 
regression rate and improve the survival outcomes of patients suffering from metastatic non-small 
cell lung cancer. Patients treated with chemotherapy did not survive after a two year period but 5-
year survival was achieved in 6% of patients treated with both MLT and chemotherapy. Moreover, 
the authors reported that chemotherapy was better tolerated in patients treated with MLT (Lissoni et 
al., 2003). It was reported in a previous study that MLT elicits its anti-cancer activity via 
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immunomodulatory action, oncostatic activity, antioxidant properties, anti-inflammatory effects and 
anti-angiogenic activity (Lissoni et al., 2001). However, further investigations are required to fully 
elucidate the mechanisms involved in MLT’s anti-cancer activity. 
In summary, to the best of our knowledge, we are the first to demonstrate that MLT improves cardiac 
function in a tumor-bearing rat model of acute DXR-induced cardiotoxicity. The underlying 
mechanisms regarding the cardioprotective effect of MLT during DXR-induced cardiotoxicity is likely 
attributed to decreased apoptotic activity and the increased expression of mitochondrial fusion 
proteins as well as PGC-1α and SIRT1 observed in this study. Furthermore, MLT enhanced the anti-
cancer activity of DXR, which suggests that MLT is dually cardioprotective and oncostatic. 
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Chapter 5 
 
Conclusion  
In the clinical oncology setting, doxorubicin (DXR) has proven to be a potent anti-neoplastic agent 
and is widely used to treat various cancers. Regrettably, it is apparent that this anti-neoplastic 
agent is a double-edged sword as it is highly toxic to the heart. DXR is known to accumulate in 
cardiac mitochondria and induce a vicious cycle of free radical production which leads to 
mitochondrial dysfunction and culminates in cardiomyocyte cell death. In view of this clinical 
impediment, the pineal indoleamine, melatonin (MLT) has proven to be beneficial in the context 
of DXR-induced cardiotoxicity as it protects mitochondria against free-radical damage induced by 
DXR. However, apart from MLT’s potent antioxidant activity, other mechanisms by which MLT 
confers mitochondrial and subsequent cardiac protection during DXR-induced cardiotoxicity 
remains to be explored. 
In our study, we first confirmed the finding of others by demonstrating that pre-treatment with MLT 
does suppress mitochondrial ROS production and preserve mitochondrial membrane potential 
during DXR-induced cardiotoxicity. In addition, we have demonstrated that pre-treatment with 
MLT during DXR-induced cardiotoxicity improves mitochondrial morphology, upregulates 
mitochondrial fusion, restores the electron transport system (ETS) capacity and the mitochondrial 
spare respiratory capacity (MSRC) thereby increasing the cellular ATP content in cardiomyocytes. 
Although we have demonstrated that pre-treatment with MLT increases Pink1 and PARKIN 
activity during DXR-induced cardiotoxicity, further work needs to be conducted to confirm that pre-
treatment with MLT promotes the clearance of damaged mitochondria by mitophagy in our study. 
The preservation of mitochondrial function by pre-treatment with MLT during DXR-induced 
cardiotoxicity is strongly associated with decreased cardiomyocyte apoptosis and improved 
cardiac function. Furthermore, we have demonstrated that MLT enhances the anti-neoplastic 
activity of DXR and suppresses the growth of tumors whilst maintaining its cardioprotective effects. 
SIRT3 activation has been shown to promote ATP production in the heart and inhibit ROS 
production. The effect of pre-treatment with MLT on SIRT3 activation was only observed in our in 
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vitro model of DXR-induced cardiotoxicity and could possibly be influencing the protective 
mitochondrial effects we have observed in our in vitro model. Other studies have reported that the 
activation of PGC-1α influences proteins involved in mitochondrial fission and fusion, maintains 
mitochondrial membrane potential and increases ATP production. Furthermore, it is known that 
SIRT1 is an upstream regulator of PGC-1α. SIRT1 activation alone has been shown to suppress 
apoptotic proteins and decrease ROS production. Since, pre-treatment with MLT increased the 
expression of SIRT1 and PGC-1α  in both in vitro and in vivo models of DXR-induced cardiotoxicity 
in our study, we propose that the underlying mechanisms by which MLT elicits its anti-apoptotic 
effects and maintains mitochondrial function during DXR-induced cardiotoxicity is possibly via a 
SIRT1 and PGC-1α dependent signaling pathway. The effect of MLT on mitochondrial function 
and the potential mechanisms by which MLT confers mitochondrial protection during DXR-
induced cardiotoxicity is summarized in Figure 5.1. 
Indeed, the versatile effects of MLT on cardiac mitochondria, its potent antioxidant action as well 
as its ability to modulate sirtuin activity and cell death regulators has shown to be beneficial in 
mitigating DXR-induced cardiotoxicity. Moreover, the beneficial effects of melatonin as an 
adjuvant therapy in reducing the side effects of chemotherapy and improving the survival outcome 
of cancer patients is well established however, there is a critical need for understanding the dual 
cardio-protective and oncostatic nature of MLT. Future studies should focus on elucidating the 
effect that MLT has on mitochondria in the context of oncology using clinically relevant in vivo 
models such as tumor-bearing models of DXR-induced cardiotoxicity. Such studies would aid in 
further exploiting the use of MLT as an adjuvant therapy and advance the current treatment 
strategies in the clinical oncology setting.  
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Figure 5.1: The effects of pre-treatment with MLT during DXR-induced cardiotoxicity. The figure summarizes 
the effects of DXR (red arrows) and DXR+MLT (blue arrows) during that were found in our study. Furthermore, the 
possible mechanisms by which MLT confers mitochondrial protection and reduces apoptosis is also indicated 
(green and blue dashed lines).Abbreviations- DXR: doxorubicin; MLT: melatonin; ROS: reactive oxygen species; 
ATP: adenosine tri-phosphate; ETS: electron transport capacity; MSRC: mitochondrial spare respiratory capacity; 
PARP: poly [ADP-ribose] polymerase; Drp1: dynamin-related protein 1; hFis1: mitochondrial fission 1 protein; 
OPA1: optic atrophy protein 1; Mfn1/2: mitofusin1/2; SIRT1/3: sirtuin 1/3; PGC-1α: Peroxisome proliferator-
activated receptor gamma co-activator 1alpha; Pink1: PTEN-induced putative kinase 1; Parkin: Parkison protein. 
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